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 ABBREVIATIONS 
PQ  -  Paraquat 
SOFA  - Sequential Organ Failure Assessment Score 
ARDS - Acute Respiratory Distress Syndrome 
AKIN  - Acute Kidney Injury Network Score 
NLR  -  Neutrophil to Lymphocyte Ratio 
MAP  -  Mean Arterial Pressure  
ABG  -  Arterial Blood Gas Analysis 
HB  -  Hemoglobin  
GCS  -  The Glasgow Coma Scale 
PH  -  Potential of Hydrogen  
Pao2  -  Partial Pressure of Arterial Oxygen  
PaCO2 -  Partial Pressure of Arterial Carbon Dioxide  
Hco3  -  Bicarbonate 
PT  - Pulse Therapy 
HD  - Hemodialysis 
MV  - Mechanical Ventilation 
Pao2/Fio2 -  Ratio of Arterial Oxygen Partial Pressure to Fractional  
   Inspired Oxygen. 
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INTRODUCTION 
Paraquat poisoning is a severe major problem in many developing 
countries.  Following ingestion of small amounts of the liquid concentrate, 
pulmonary oedema, cardiac failure, renal failure, liver failure and convulsions 
caused by central nervous system involvement. Highly toxic via ingestion, one 
teaspoonful of paraquat is fatal under these circumstances; paraquat death from 
multiple organ failure may follow within hours or days. There is no antidote for 
paraquat poisoning. In spite of its high toxicity, mortality and the lack of an 
antidote the WHO classified paraquat only as moderately hazardous. It is 
classified asunder ‘highly’ hazardous in the USA 
 
In Our Poison Centre, Rajiv Gandhi Government General Hospital, 
Chennai, 50  Cases  Of Acute  Paraquat Poisoning Admitted from  august 2017 
to July 2018.At Our Hospital All The Patients Are Treated Using A Standard 
Detoxification Protocol. This Protocol Consists Of Repeated Pulses Of 
Methylprednisolone And Cyclophosphomide Followed By Dexamethasone 
Therapy. 
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AIMS AND OBJECTIVES 
1. To investigate the hematological indices, assessment scores and 
evaluates the predictor of prognosis in patients with acute paraquat 
poisoning 
2. To identify predictors in acute paraquat poisoning and determine the 
association between these parameters. 
3. Predictor of Acute respiratory distress syndrome by using SOFA score, 
AKIN score on admission, 24hrs, and48 hrs 
4. By using assessment scores we can predict the ARDS earlier to start 
pulse therapy as early as possible 
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REVIEW OF LITERATURE 
Historical Background 
Paraquat (herbicide) was first prepared  for commercial purposes   as a 
Gromoxone in 1961, gromoxone 24% non selective fast acting herbicide. 
Paraquat is a highly toxic chemical that is widely used as an herbicide (plant 
killer, weed killer), mostly for weed and grass control. In Worldwide, paraquat 
is still one of the most commonly used herbicides. In USA due to its toxicity 
paraquat is available for use only by commercially licensed users and classified 
under the category of highly hazardous. 
Paraquat is highly toxic chemical that is widely used as an 
herbicide(plant killer),uniquely controls wide spectrum of weeds, rain fast, 
inactivated when contact with a soil, it prevent the soil erosion and cost 
effective. primarily for weed and grass control. The most likely route of 
exposure to paraquat that would lead to poisoning in ingestion (swallowing), 
less accidental. Pq is a contact herbicide which rapidly kills the green parts of 
the plants under the action of sunlight. Paraquat poisoning is characterized by 
acute lung injury, pulmonary fibrosis, respiratory failure, and multi-organ 
failure, resulting in a high rate of mortality and morbidity. 
WEED KILLERS 
Herbicides, also called as weedkillers or plant killers, they are chemical 
substances which are used to control unwanted plants. Selective herbicides 
control specific or selective weed species, while leaving the desired crops, 
while non-selective herbicides that is total weed killer (commercial used 
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products) can be used to clear waste ground, industrial and construction sites, 
as they kill all plant material with which they come into contact. 
 Apart from selective/non-selective, other important distinctions include 
products persistence residual action of products,’ (how long the product stays 
in place and remains active), means of uptake (route of absorption by above-
ground foliage only, through the roots, or by other means), and mechanism of 
action.  
Herbicides are used to destroy unwanted vegetation, act by interfering 
with growth of weeds and plant hormones, herbicides can be applied directly to 
the plant, applied to the soil or sprayed .Historically, products such as common 
salt and other metal salts were used, and in some countries a number of these 
are banned due to their persistence in soil, and toxicity and groundwater 
contamination concerns.  
Mechanism of action   
1. Inhibit the Acetyl coenzyme A carboxylase (ACCase)  in lipid synthesis 
2. Paraquat catalyze the formation of reactive oxygen species superoxide 
free radicals 
3. PQ will undergo redox cycling 
4. Inhibit mitochondrial and cytoplasmic malate dehydrogenase in electron 
transport chain 
5. Lipid peroxoidation of mitochondrial inner membrane 
6. Interfering with intracellular electron transport through the inhibition of 
NADP reduction to NADPH 
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7. Inhibit the acetolactate synthase (ALS) enzyme (acetohydroxyacid 
synthase)   branched-chain amino acids (leucine, and isoleucine 
8. Inhibit the Enolpyruvylshikimate 3-phosphate synthase enzyme 
(EPSPS) in the synthesis of the amino acids tryptophan, phenylalanine 
and tyrosine. 
Synthetic herbicides 
1. Aminopyralid 
2. Atrazine 
3. ClopyralidGlufosinate ammonium 
4. Fluazifop (Fuselade Forte) 
5. Fluroxypyr 
6. Imazamox 
7. Paraquat 
8. Pendimethalin 
Organic herbicides 
1. Corn gluten meal (CGM) 
2. Vinegar 
3. D-limonene (citrus oil) 
4. Saltwater or salt 
5. Monocerin 
6. Steam 
 
6 
 
USES OF PARAQUAT 
• Paraquat is  relatively non-selective foliage-applied contact herbicide, 
weed killer 
• It is inactivated on contact with almost all naturally occurring soils 
• It provided the greatest breakthrough in chemical weed control at the 
time of its discovery.  
• Inactivation on contact with soil means that no biologically active 
residues remain in the soil, thus allowing planting or sowing to be 
carried out almost immediately after spraying.  
 
PREPARATIONS   
Paraquat is available as a liquid concentrate (24percent), as granules 
subsequently dissolved in water (2.5 to 10 percent), or as an aerosol (0.2 
percent). 
Paraquat compounds 
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IUPAC name 
1, 1′-Dimethyl-4,4′-bipyridinium dichloride Paraquat is an oxidant that 
interferes with electron transfer, addition of one electron gives the radical 
action [MV] 2+ + e− ↔ [MV]+ 
The radical cation is also susceptible to further reduction to the neutral 
[MV] + + e− ↔ [MV]0 
As an herbicide, paraquat acts by inhibiting photosynthesis. In sunlight-
exposed plants, it accepts electrons from photosystem I (ferredoxin, which is 
presented with electrons from PS I) destructive reactive oxygen species are 
produced. In forming these reactive oxygen species, the oxidized form of 
paraquat is regenerated, and is again available to shunt the electrons from 
photosystem I to restart the cycle. 
 
OTHER NAMES 
 Paraquat dichloride 
 Methyl viologen dichloride 
 Crisquat Dexuron 
 Esgram 
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 Gramuron 
 Ortho Paraquat CL 
 Para-col 
 Pillarxone 
 Tota-col 
 Toxer Total 
 PP148 Cyclone 
 Gramixel 
 Gramoxone 
 Pathclear 
 AH 501. 
Metabolism, elimination, kinetics 
 Toxic amounts of PQ absorbed after oral ingestion, the greater part of 
the ingested paraquat is eliminated unchanged in the feces and eliminated 
through the kidney, Paraquat can also be absorbed through the skin, if it is 
damaged. The mechanisms of the toxic effects of paraquat cause single-
electron reduction oxidation reaction, resulting in depletion of cellular NADPH 
and   of oxygen such as the superoxide radical.  
1. Highly polar and corrosive substance. 
2. Rapidly but incompletely absorbed from the gut 
3. Maximum tissue levels reach 6 hours after ingestion. 
4. Paraquat has no significant metabolism 
5. Elimination is primarily by kidneys 
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 Absorbed paraquat is distributed through the bloodstream to 
practically all organs and tissues of the body, but no prolonged storage takes 
place in any of the tissues.  The lung selectively accumulates paraquat from the 
plasma by an energy-dependent process, since the removal of the absorbed 
paraquat occurs mainly via kidneys, an early onset of renal failure following 
uptake of toxic doses and marked effect on the paraquat elimination and 
distribution and on its accumulation in the lung. 
TOXICITY  
 Paraquat exerts its herbicidal activity by inhibiting  reduction of 
NADP to NADPH during photosynthesis and forming superoxide, singlet 
oxygen, hydroxyl, and peroxide radicals .These toxic o2 radical species 
subsequently to destroy  the lipid cell membranes by polymerization of 
unsaturated lipid compounds  and human tissue toxicity likely results from a 
similar oxidative mechanism. After oxidative destruction, recruitment of 
inflammatory cells exacerbates injury. 
 The lung and kidney are the primary target organs in paraquat toxicity. 
In the lung, a polyamine transporter protein leads to preferential accumulation 
in alveolocytes; the high local oxygen tension that generates the high levels of 
toxic oxygen species and subsequent damage. In esophagus Paraquat, a mild 
caustic agent, produces only grades 1, 2a, and 2b esophageal injury(1).  
Ingestion of moderate amounts of paraquat causes the sequence of 3 stages. 
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Stage I:  
 Lasting for 1 to 5 days, Local corrosive action Hemoptysis, ulcerations 
of mucous membranes, nausea, diarrhea, oliguria. 
Stage II: 
 Lasting for 2 to 8 days. Signs of hepatic failure, kidney, cardiac 
damage, jaundice, fever, tachycardia, myocarditis, respiratory distress, 
cyanosis, elevated BUN, creatinine, serum alkaline phosphatase, serum 
bilirubin, serum transaminases, low prothrombin. 
Stage III:  
 Lasting for 3-14 days. Pulmonary fibrosis, cough, dyspnea, tachypnea, 
edema, pleural effusions, atelectasis, low arterial oxygen tension, increased 
alveolar oxygen tension gradient, respiratory failure. 
Ingestion of small amounts less than teaspoon level may cause minor 
symptoms followed by full recovery. Overall mortality rate of accidental 
poisoning is estimated to be 33 - 50%. 
 In the kidney, the principal organ of excretion, paraquat is 
concentrated during excretion, often leading to acute tubular necrosis, acute 
kidney injury, which may occur soon after ingestion (within 24 hours). 
Paraquat-induced renal dysfunction may decrease paraquat excretion; thereby 
increasing overall toxicity. Various compounds may ameliorate the toxic 
effects of paraquat, thereby suggesting different mechanisms of injury 
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 Lipid peroxidation may be enhanced by the iron radicals, since 
removal of iron by chelating agent desferoxamine reduces toxicity in bacterial 
preparations or in normal mice, as well as in vitamin E deficient rats. 
 Exogenous glutathione and n- acetylcysteine, a donor of glutathione, 
may protect against injury Sulfite or thiosulfate (redox agents) may be 
protective by reversing oxidized glutathione, which competes with glutathione 
for peroxide, hydroxyl, and superoxide radicals.  
 Animal studies suggest that salicylates help prevent paraquat induced 
lung, kidney, and liver injury. The mechanisms may involve interruption of 
pro-inflammatory factors (NFκB), scavenging of reactive oxygen species, and 
inhibition of both myeloperoxidase pathways and platelet aggregation. There is 
also some evidence that the salicylates can chelate bipyridyls. Some of these 
agents have been administered to patients poisoned with paraquat with varying 
success.  
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Clinical manifestations   
 Patients are principally exposed to paraquat via the skin, lungs, and 
gastrointestinal tract. 
Skin: 
 Direct exposure via injured the skin and lungs infrequently results in 
systemic toxicity. Inhalation and dermal absorption of paraquat is poor, 
particularly if its injured, Whilst spraying, some solution adhered to their skin. 
The skin developed erythema followed by blistering and hemorrhagic diabrosis 
Among  paraquat sprayers with heavy skin exposure, skin rashes (particularly 
on scrotal and intergluteal areas), cracked nails, and epistaxis may occur. 
 
PARAQUAT EXPOSURE AMONG FARMERS
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Systemic reactions are not observed among knapsack paraquat sprayers 
with heavy skin exposure. Cutaneous absorption appears to vary with skin 
integrity one study that evaluated the dermal absorption of the closely related 
chemical diquat reported that 0.4 percent of a topical dose was absorbed from 
an unoccluded site, 1.4 percent was absorbed from an occluded site; and 3.8 
percent was absorbed from an occluded and damaged dermal site Inhalation of 
spray is unlikely to cause systemic toxicity because of its low vapor pressure 
and large droplets. Inhaled smoke from paraquat-contaminated marijuana is 
also less able to produce systemic illness, this is due to the low concentration of 
paraquat, and the thermal-dependent conversion of paraquat to nontoxic 
bipyridines Gastrointestinal tract     
 Oral ingestion of paraquat causes significant amounts systemic 
toxicity as well as direct injury to the gastrointestinal tract. Death may result 
14 
 
from multiorgan failure, including severe hepatotoxicity, direct local toxicity. 
after a person ingests a large amount of paraquat, and he or she is immediately 
likely to have pain and swelling of the mouth and throat. The next signs of 
illness following ingestion are gastrointestinal (digestive tract) symptoms, such 
as nausea, vomiting, abdominal pain, and diarrhea (which may become 
bloody). 
Severe gastrointestinal symptoms may result in dehydration (not enough 
fluids in the body), electrolyte abnormalities (not enough sodium and 
potassium in the body), and low blood pressure 
 
 The major acute local gastrointestinal effects result from the caustic 
properties of paraquat, particularly the concentrate ulceration of the lips, 
tongue, and pharynx (pseudomembrane) may be observed within 1-2 days of 
ingestion. Esophageal ulceration may proceed to esophageal perforation. 
Lungs   
  Inhalation of paraquat-contaminated may cause local toxic effects on 
bronchi, possibly resulting in hemoptysis. After ingestion, the greatest paraquat 
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concentration is found in the lungs and the concentration peaks in 5 to 7 hours.  
Paraquat poisoning causes multiple organ damage. Paraquat selectively 
accumulates in the lung where free radicals are formed and lipidperoxidation is 
induced. The capillary endothelial and epithelial cells of the lungs are the main 
targets of damage. These results in the development of diffuse alveolitis 
followed by extensive pulmonary fibrosis.  The development of pulmonary 
fibrosis is usually delayed up to 3 to 14 days, but it is progressive. 
 
Definition of ARDS 
         ARDS was defined as acute onset of bilateral pulmonary infiltrates, a 
ratio of PaO2 to fraction of inspired oxygen (FiO2) of ≤200 mmHg, and 
pulmonary artery occlusion pressure of ≤18 mmHg or absence of left atrial 
hypertension. (9)High-resolution computed tomography (HRCT) is an 
excellent tool for detecting paraquat-induced lung injury.  
 
ARDS mechanism of lung injury: 
• Activation of inflammatory mediators and cellular components resulting 
in damage to capillary endothelial cells and alveolar epithelial cells 
• Increased permeability of alveolar capillary membrane 
• Influx of protein rich edema fluid and inflammatory cells into air spaces 
Dysfunction of surfactant 
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ARTERIAL BLOOD GAS ANALYSIS IN ARDS 
EARLY STAGE 
PaO2 <60mmof hg 
Paco2<35mm hg 
Ph may be normal or increased 
Pio2/fio2, <200 
Later stage 
Pao2 more falling despite oxygen therapy 
Paco2> 45 mm hg showing respiratory acidosis 
Hco3<22meq/l 
Pao2/fio2< 200 
 
ACUTE LUNG INJURY 
 
  
MECHANICAL VENTILATION PTOTOCOL FOR ARDS
The predominant finding within the first 7 days is areas of ground
attenuation that change into areas of consolidation 
bronchiectasis and areas of irregular lines on follow
 
 HRCT CHEST
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associated with 
-up HRCT scans.
   B/L LUNG INFILTRATION
  
CHEST X –RAY 
 ARDS
 
-glass 
(4) 
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HRCT scan obtained The lung inflammation observed in ARDS can be 
precipitated by diverse disease processes, including both intrapulmonary ones 
(infection or aspiration) and extrapulmonary ones (shock or extensive trauma). 
The acute inflammation of the lung associated with ARDS often leads to the 
formation of pulmonary fibrosis, which leads to severe functional lung 
impairment. Pulmonary fibrosis is an fatal disorder characterized by connective 
tissue deposition within the terminal air spaces resulting in loss of lung 
function and eventual such as transforming growth factor (TGF)-α and TGF-β, 
in view of the association between mortality and pulmonary fibrosis in 
established ARDS. Tumor necrosis factor-α (TNF-α)is secreted by monocytes 
or macrophages,including those of the alveolar space, after exposure to 
bacterial lipopolysaccharides and a variety of proinflammatory mediators. 
Transforming growth factor-b1 (TGF-β1) is a cytokine critically involved in 
acute lung injury and endothelial cell (EC) barrier dysfunction. TGF-β1 has 
been specifically implicated in the pathogenesis of pulmonary fibrosis and 
hepatic fibrosis 
Paraquat, a quaternary nitrogen herbicide, is a highly toxic compound 
for humans and animals and many cases of acute poisoning and death have 
been reported over the past few decades’ respiratory failure. Cytokines are 
involved in the variety of inflammatory lung diseases, but their pathogenic role 
and their significance as diagnostic tools are still controversial. Many 
inflammatory cytokines are involved in the pathogenesis of ARDS, and some 
have prognostic significance. An important role has been suggested for 
cytokines that regulate 
paraquat ingestion shows diffuse ground
CT CHEST shows pneumomediatinum after Paraquat 
 
Pneumomediastinum following paraquat poisoning is
according to this observation but comprised
other surveys. The development of pneumomediastinum following paraquat
ingestion could be explained by the Macklin effect.
acute inflammation of the lung, which
and late pulmonary fibrosis.
19 
mesenchymal cell proliferation and fibrosis;
-glass opacity in both lungs.
 
Ingestion
 
 38.45% and 18.75% of cases in 
 Paraquat toxicity
 results in necrotizing lung parenchyma, 
 
1 week after 
 
, 
 
uncommon 
 
 causes 
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Hence the lung will become stiff, predisposing these patients to 
barotrauma. Free air might track from ruptured alveoli along the peribronchial 
vascular sheaths toward the hilum of the lung, from there, it might extend 
proximally to the mediastinum Pneumomediastinum in paraquat poisoning 
often designates a grave prognosis, with a patients experience moderate to 
severe poisoning and die within 1–2 weeks from pulmonary fibrosisData on the 
clinical predictors of ARDS after paraquat ingestion are lacking in the 
literature. Paraquat toxicity has been questioned and discussed for decades 
among international and national regulatory bodies, and nongovernmental 
organizations and many countries have banned its commercial use. (5)In 
theory, SOFA scores might be good predictors of ARDS in patients with 
paraquat poisoning. Finally, the reason for including the AKIN score is another 
similar cross talk between renal and pulmonary damage.(6) SOFA and AKIN 
scores (Table 1 and 2) 
SOFA SCORE 
 0 1 2 3 4 
PaO2/FiO2 >400 301-400 201-300 
101-200 with 
respiratory 
support 
<100 with 
respiratory 
support 
Platelets 
(1000/µL) >150 101-150 51-100 21-50 <20 
Bilirubin 
(mg/dL) <1.2 1.2-1.9 2.0-5.9 6.0-11.9 >12.0 
Hypotension MAP>70 
mmHg 
MAP<70 
mmHg 
Dopamine 5 
or 
dobutamine 
(any dose)* 
Dopamine >5 
or epi<0.1 or 
norepi<0.1* 
Dopamine 
>15 or 
epi>0.1 
GCS 15 13-14 10-12 6-9 <6 
Cr (mg/dL) or 
UO <1.2 1.2-1.9 2.0-3.4 
3.5-4.9 or 
<500 mL/d 
>5.0 or 
<200 mL/d 
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AKIN SCORE 
Category Serum Cr. Criteria Urine Output Criteria 
Stage 1 
Increase in serum Cr of >0.3 mg/dL 
of increase to >150% to 200% (1.5 to 
2-fold) from baseline 
<0.5 mL/kg/h for 
 more than 6 h 
Stage 2 Increase in serum Cr to >200 <0.5 mL/kg/h for  
more than 12 h 
Stage 3 
Increase in serum Cr to >300% (3-
fold) from baseline (or serum Cr of 
>4.0 mg/dL with an acute increase of 
at least 0.5mg/dL 
<0.3 mL/kg/h for 24 h 
or anuria more than12 h 
 
The following data were collected, SOFA and AKIN scores 48 hours 
after admission (SOFA48, AKIN48-h), and time to ARDS (ARDS patients) or 
nadirPaO2 (non-ARDS patients). The SOFA score consists of 6variables, each 
representing an each organ system. Each organ system is assigned a point value 
from 0 (normal) to 4 (high degree of dysfunction/failure). 
 The AKIN criteria classify acute kidney injury into 3 stages of severity 
(stages 1, 2, and 3)(10)An experimental study revealed an elevation of 
macrophage-derived inflammatory products and an increase in pulmonary 
vascular permeability after isolated renal ischemia/reperfusion injury in rats. 
hence, acute kidney injury following paraquat poisoning may result from the 
toxicity of paraquat itself or as a renal complication of acute lung injury.(14) 
Pulmonary edema may be observed 24 to 48 hours after ingestion; this may 
evolve to a condition resembling adult respiratory distress syndrome, which 
may progress to pulmonary fibrosis. 
22 
 
The pulmonary changes depend upon the quantity of paraquat ingested 
and the time of ingestion. In the first week after ingestion, radiographic 
findings may include diffuse consolidation, pneumomediastinum with or 
without pneumothorax and subcutaneous emphysema, and cardiomegaly with 
widened superior mediastinum. Pulmonary fibrosis may develop after a few 
days. Although this last event is usually irreversible, there have been isolated 
reports of full recovery (even with severe pulmonary involvement). Death 
usually occurs within 1-2 weeks, but may be observed up to six weeks after 
ingestion 
Eyes  
 Concentrated paraquat dichloride 24% splashes may cause severe eye 
irritation which may result in loss of superficial areas of the corneal and 
conjunctival epithelium; ulcerated areas are at risk from secondary infection. 
Corneal edema may persist for up to 3 to 4 weeks with temporary blurring of 
vision Corneal exposure to paraquat can cause ulceration and scarring. 
Systemic toxicity   
 Systemic toxicity principally results from the oral ingestion of 
moderate to large amounts of paraquat. Ingestion of moderate amounts , The 
following subacute toxic effects may occur with the oral ingestion of amounts 
of paraquat approximately between 4 to 30 mL of the liquid concentrate 
Renal failure  
 Renal failure may occur within 2 to 6 days of ingestion, which further 
impairs paraquat excretion. Proximal renal tubule dysfunction may be 
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observed. At high doses, paraquat can cause acute tubular necrosis, leading to 
oliguric or nonoliguric renal failure. Renal excretion of paraquat is markedly 
reduced, resulting in higher serum concentrations and increases in paraquat 
accumulation in organs, such as the lung and liver. Although, renal damage is 
reversible if patients have ingested <40 mg/kg paraquat(7)Paraquat is 
eliminated mainly by the kidney and acute kidney failure is a recognized 
complication of paraquat poisoning, with reports of botholiguric 7,8 and 
nonoliguric 9,10 cases. Beebeejaun and coworkers found proximal renal 
tubular necrosis by histopathological examination of a fatal case of paraquat 
poisoning, consistent with the observations of Ecker and colleagues, who 
observed that functional paraquat renal toxicity was restricted to the proximal 
nephron in mice.  
Paraquat poisoning may causes Fanconi syndrome with a variety of 
proximal tubular abnormalities, including glycosuria, phosphaturia and 
aminoaciduria, as shown in the series of 3 cases reported by Vaziri and 
colleagues.(23,24) The precipitation of acute kidney injury was mostly 
multifactorial, hypovolemia, septicaemia, and multiorgan failure. Early 
referrals, absence of multi organ dysfunction and less amount of paraquat 
consumption seems to be the key factors for recovery of kidney function 
Hepatotoxicity  
 Manifestations include jaundice, hepatic failure and biochemical 
derangements such as raised transaminases and bilirubin. A total of 187 
patients were referred for management of intentional paraquat ingestion 
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between 2000 and 2010. Patients were categorized into two groups according 
to their hepatic complication, i.e. with (N = 87) or without (N = 100) toxic 
hepatitis(3) 
Metabolic acidosis  
 This may be caused by a variety of abnormalities, including 
myocardial failure (myocarditis and epicardial hemorrhage with arrhythmias), 
adrenal gland insufficiency (due to necrosis), systemic hypotension, severe 
hypoxemia, and/or renal failure.  
Ingestion of massive amounts   
 Major organ failure, frequently resulting in death, may occur with 
massive ingestion (greater than 30 mL of concentrate). These include cardiac 
failure, renal failure (which may be observed within hours of ingestion), 
hepatic failure, pulmonary edema, and/or central nervous system involvement 
(resulting in convulsions). Death may occur within several hours to a few days. 
patients admitted to the Institute of Pesticide Poisoning, Soonchunhyang 
University Cheonan Hospital from May to September 2011. Cut-off point for 
time to negative conversion of the urine dithionite test with a cut-off value of 
30.5 hr to a negative urine dithionate test, the sensitivity and specificity for 
identifying patients 
LABORATORY DETECTION   
         A qualitative urine test for paraquat, which detects concentrations of  
1 mg/mL or above (1 ppm), can be made by adding 2 mL of a 1 percent 
solution of sodium dithionite in 1 N sodium hydroxide to 10 mL of urine; a 
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blue color indicates the presence of paraquat. A presumptive diagnosis of 
paraquat poisoning was based on exposure history, clinical effects, and 
physical and Laboratory examinations, especially the urine sodium dithionite 
screening test. The urine sodium dithionite reaction depended on the reduction 
of paraquat by sodium thionite under alkaline conditions to form stable, blue-
colored radical ions. The generation of a strong navy or dark blue color 
generally indicates significant paraquat ingestion indicates a poor prognosis. 
                  The urine test was used as a paraquat screen, and a confirmatory 
diagnosis of paraquat poisoning was only possible by checking blood paraquat 
Concentrations (spectrophotometry) (8).patients ingested concentrated PQ 
(22%-23% per volume) while attempting suicide and werts in the mortality 
group were 81.0% and 60.0%, respectively (AUC, 0.725).Similarly, the 
sensitivity and specificity for identifying patients in the mortality group were 
71.4% and 75.0% with a cut-off value of 34.5 hr. Using these data, we selected 
a time to negative conversion of the urine dithionite test of 34.5 hr as a cut-off 
value. 
Time to a negative dithionite urine test, mortality rate, the incidence of 
acute kidney injury and acute respiratory failure were Significantly higher in 
the “above 34.5 hr patient group” than in The “below 34.5 hr patient group” 
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URINE SODIUM DITHIONITE TEST 
 
 
 
 
 
 
  
SPECTROPHOTOMETRIC 
 
 
The Severity of prognosis of acute PQ poisoning determined by ingested 
dose. However serum PQ concentration is not available in most hospital we 
could not confirm the précised the amount of PQ ingested, because they 
remember the exact time and amount because they were upset and / or drunken 
when they Ingested.
Spectrophotometry.   
 The results of the negative dithionite urine test. 
and high pressure liquid chromatography can detect levels of 1 to 2 
microgram/mL with some accuracy.
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ANALYSIS OF PLASMA/URINE 
PARAQUAT 
 Seum PQ concentration confirmed by HPLC, 
Gas chromatography 
 
 
did not 
28 
 
         RADIOIMMUNOASSAY can detect and measure levels well below 0.1 
microgram/mL. Fatal outcomes are usually associated with plasma levels 
greater than 0.2 mg/mL at 24 hours after ingestion and 0.1 mg/mL at 48 hrs 
               NEUTROPHI LYMPHOCYTE RATIO (NLR) has emerged as a 
potent composite inflammatory marker. Among the various inflammatory 
indicators, (15, 16, 17) NLR is a sensitive inflammatory and prognostic 
indicator in many diseases including sepsis, stroke, cardiac disorders, and 
cancer etc. Due to the similar inflammatory response in PQ poisoning, the NLR 
may also be used as prognostic indicator to predict mortality in patients with 
PQ poisoning. The aim of the present study is to investigate the prognostic 
value of the hematological parameters and neutrophil-lymphocyte ratio (NLR) 
in patients with acute PQ poisoning. Moreover, Leukocyte, neutrophil counts, 
and NLR can estimate prognosis in patients with acute poisoning.(18) 
As a powerful redox cycling agent, intracellular PQ alternates the 
process of reduction and re-oxidation. Reactive oxygen species (ROS) are 
generated during this process and can cause subsequent cellular damage such 
as lipid peroxidation (19) 
 The peripheral leucocytosis is part of the more general response to 
stress, and neutrophil has been recognised as an early part of the inflammatory 
response (20). Leukocytosis, neutrophilia, and lymphocytopenia can be 
detected in the acute clinical course when the oxidative stress is increased (21) 
 Some studies have showed that the Neutrophil-lymphocyte ratio 
(NLR) is an indicator of prognosis in many diseases including acute poising 
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(22). NLR is a combination of these two biomarkers involved in the 
inflammatory process, which indicated the balance of the inflammatory and 
immune systems, making the NLR a useful index that reflects systemic 
inflammation responses. 
MANAGEMENT 
Flowchart for the early management of paraquat poisoning
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 In addition to appropriate supportive care, management of paraquat 
poisoning is directed at removing paraquat from the gastrointestinal tract, 
increasing its excretion from blood, and preventing cellular damage with 
selected agents. 
 Prevention of  paraquat from gastrointestinal absorption   
 
Fuller's earth, bentonite, and activated charcoal have all been employed 
in paraquat poisonings. Fuller's earth may be administered as a 30 percent 
suspension, along with magnesium sulfate to produce a catharsis. Bentonite 
may also be administered as a 6 to 7.5 percent suspension. Activated charcoal 
administered in a dose of (1 g/kg up to 50 g) doses. We do not routinely 
recommend gastric lavage, although this modality may be considered if a 
patient presents immediately after ingestion. Gastrointestinal decontamination, 
if employed, should be performed as quickly as possible owing to the rapid 
absorption of paraquat after oral exposure.  
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1. TO PREVENT THE GIT ABSORBTION  
 Within 2-4 h use activated charcoal or Fuller's earth 
2.NASOGASTRIC TUBE  
 To prevent the aspiration Pharyngeal/oesophageal burns or PQ in 
urine, Insert prophylactically as early as possible as swallowing becomes 
difficult later. 
3.SEMI QUANDITATIVEURINE DITHIONITE TEST 
 It’s a screening test, used for all patients, If negative, repeat within 
24hrs, it indicate the prognosis. Survival expected if negative test – confirm 
with plasma paraquat 
4. PLASMA PARAQUAT 
 Indicate prognosis, serum paraquat level is not available in most 
hospital, the amount of ingestion difficult to estimate particularly in patients 
presenting with confusion, confirmed by HPLC 
OTHER ROUTINE TESTS: 
 CBC, LFTs, RFT, ABG, Repeat at least daily and when clinically 
indicated, Look for reversible causes. Progressive changes indicate prognosis 
5. MONITOR FLUID BALANCE   
 Declining urine output, correct fluid balance and screen for acute renal 
failure 
6. INTRAVENOUS FLUIDS  
 Indicated for Inability to swallow, hypotension 
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7. HAEMOPERFUSION / HAEMODIALYSIS 
 Presentation within 2 h. acute renal failure without pneumonitis, most 
likely of use early and in cases with ‘borderline exposures’. Futile in very 
severe or late poisoning. 
8. MONITOR RESPIRATORY RATE AND OXYGEN SATURATION. 
 Avoid oxygen, oxygen itself harmful to the acute paraquat poisoning. 
Look for treatable causes (e.g. infection and pneumothorax). Acute 
pneumonitis (early) and fibrosis (late) indicate very poor prognosis 
9. MONITOR HEMODYNAMIC STATUS  
 Hypotension not responsive to fluid indicates a very poor prognosis. 
10. MONITOR LEVEL OF CONSCIOUSNESS  
 If CNS toxicity secondary to hypoxia or acidosis, there is a very poor 
prognosis, monitor GCS score.  
11. PAIN RELIEF AND SEDATION 
 Pain relief with opiates and sedation with benzodiazepines as required 
12. INTUBATION AND MECHANICAL VENTILATION  
 Acute stage as for any other medical condition, Avoid in acute 
pneumonitis due to large ingestions and lung fibrosis 
13. PULSE THERAPY 
 Cyclophosphamide 15mg/kg/ day, methylprednisolone 1g/day 
followed by dexamethasone. 
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EXTRACORPOREAL REMOVAL 
 Extracorporeal removal techniques may be useful, particularly when 
the paraquat level or ingested dose is moderate to low (ingestion of 4 to 30 mL 
of concentrated paraquat). Although plasma paraquat concentrations are 
reduced with hemodialysis or hemoperfusion, redistribution from tissue or 
continued absorption from the gastrointestinal tract may cause a rebound in 
plasma concentration in the post dialysis period.  
Hemoperfusion provides better clearance of paraquat than hemodialysis, 
and the use of hemoperfusion within 12 hours of poisoning may reduce 
mortality. A study of charcoal hemoperfusion in a dedicated pesticide treatment 
center has reported 50 survivors of 105 patients treated; a more rapid reduction 
in plasma concentrations in the survival group (compared with the 
nonsurvivors) was observed.  
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 Glucocorticoids have been used in the management of patients 
poisoned with paraquat Azathioprine, beclomethasone, bleomycin, fluorouracil, 
and fibrinolytic agents (potassium aminobenzoate) have also been used without 
benefit.  initial pulse therapy with methylprednisolone (1 g/day for 3 days) and 
cyclophosphamide (15 mg/kg/day for 2 days), followed by dexamethasone  
20 mg/day until Pao2 was >11.5 kPa (80 mm Hg) and repeated pulse therapy 
with methylprednisolone (1 g/day for 3 days) and cyclophosphamide  
(15 mg/kg/day for 1 day), which was repeated if Pao2 was <8.64 kPa (60 mm 
Hg)².Small, primarily observational studies reported mixed results about the 
effectiveness of cyclophosphamide combined with glucocorticoid.  
A subsequent systematic review of three randomized trials involving a total of 
164 patients with moderate to severe paraquat poisoning found that those 
treated with a combination of cyclophosphamide and glucocorticoids had a  
28 percent lower risk of death (RR 0.72, 95% CI 0.59-0.89) compared to those 
given standard treatment Standard treatment included gastrointestinal 
decontamination and either hemodialysis or hemoperfusion.Repeated pulses of 
Cyclophosphamide and Methylprednisolone, rather than high doses of CP and 
DEX, may result in a lower mortality rate in patients with severe PQ poisoning. 
 
LUNG TRANSPLANTATION   
 Lung transplantation has been performed in at least four patients 
without success. Serial lung transplant in one patient eventually resulted in a 
successful transplant, as the first transplant also developed paraquat toxicity. 
However, the patient was ventilator dependent due to progressive toxic 
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myopathy (paraquat toxicity) and eventually died from bronchopneumonia. 
Another patient had a successful transplant but died from complications arising 
from a ruptured bronchial anastomosis  
 
Other measures   
 Lung radiotherapy is controversial; some have reported success but 
controlled animal experiments and other clinical studies have failed to find 
benefit. Superoxide dismutase has been used in several patients without benefit. 
Deferoxamine, nitric oxide,and immunotherapy are other possible therapies, 
but data is limited and further study required. 
 
Paraquat antibodies immobilized on agarose-polyacrolein spheres 
enclosed in hemoper fusion devices have been shown experimentally to bind 
paraquat avidly from animal blood passing through the devices. Plasmapheresis 
also has been advocated, but further studies are needed before its effectiveness 
is proven. 
 
 
PREVENTION AND EDUCATION 
 
• Improved regulations of availability of herbicides and modifications of  
Packaging of herbicides may all help reduced the use of PQ as poison. 
• Adequate information to the public, regular training of health  Care 
providers, better availability of drugs/facilities and the establishment of 
poison information centres will facilitate in reducing the morbidity and 
mortality related to paraquat poisoning.  
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• Herbicide should be kept out of reach of children to prevent accidental 
Poisoning. Proper protective precautions should be taken during 
agricultural spraying to prevent inhalation and accidental ingestion of 
substance. 
 
 
  
  
 
 
MATERIALS AND METHODS 
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MATERIALS AND METHODS 
Setting:  
This study was conducted in our poison centre, Institute of Internal 
Medicine, Rajiv Gandhi Government General Hospital, Chennai. It was a 
Observational  study done during the period from August 2017 To July 2018. 
50 patients, admitted as a case Paraquat poisoning cases in our toxicology ICU 
and carries the mortality of around 99%  (case register AUG  2017 –  
july2018). Our thesis of "A STUDY OF HEMATOLOGICAL  INDICES, 
ASSESSMENT SCORES AND PREDICTOR OF PROGNOSIS IN 
PATIENTS WITH ACUTE PARAQUAT POISONING poisoning will 
surely aim in making or correcting the protocol for treatment  of acute paraquat 
poisoning and also in reducing the morbidity  and mortality of the patients 
admitted of acute paraquat poisoning with exposure irrespective of route of 
exposure, age and sex were selected and subjected for study with the consent. 
 
INCLUSION CRITERIA: 
All cases of acute paraquat poisoning admitted in our hospital 
irrespective of age and sex showing positive urine sodium dithionite test  
whose caregivers are willing to give written informed consent 
 
EXCLUSION CRITERIA: 
Other pesticide poisoning  
chronic liver disease,  
malignancy, 
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chronic kidney disease. 
Previous history of pulmonary disorders 
Negative urine sodium dithionite test 
Sample Collection and Methods  
1. Arterial BloodGas Analysis 
2. Renal Function Test, Liver Function Test, CRP 
3. complete blood count 
Methodology 
(Materials and Methods)  
 After obtaining clearance and approval from the institutional ethics 
committee and written informed consent of the caregiver, patients admitted to 
the emergency with paraquat compound consumption will be confirmed by 
urine dithionite screening test, after fulfillment of inclusion and exclusion 
criteria and enrolled in the study. All routine investigations like ABG, CBC, 
RFT, LFT, RBS, URINE dithionite test, will be performed 
Statistical methods 
Statistical analysis was done using SPSS software. The following 
Statistical methods have been employed for analysis: 
1. Chi-square test 
2. Unpaired student t-test 
3. Analysis of variance (ANOVA) 
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STATISTICAL METHODS: 
           The data was analysed using SPSS software. Pearsons correlation 
coefficient and p value were calculated to find the statistical significance. 
Variables were considered to be significant if p value < 0.05 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
OBSERVATION AND RESULTS 
 
  
OBSERVATION AND RESULTS
DESCRIPTION OF STUDY POPULATIONS
 
Chisquare value =14.016**p<0.0001
 
In our study population
between the age group of
majority.  
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Male 
78%
Age group 
< 20 Yrs 
20-50 Yrs 
> 50 Yrs 
Total 
40 
 
 
TABLE: 1  
AGE DISTRIBUTION 
 
 43.55% occupies male, number
 20-50 accounts for 77.8% cases, which forms the 
Female
4%
44%
57%
Male Female
No % No 
1 3.7% 10 
21 77.8% 13 
5 18.5% 0 
27 100.0% 23 
 
 of people 
20-50 Yrs
< 20 Yrs
 
% 
43.5% 
56.5% 
0.0% 
100.0% 
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TABLE : 2  
SEX DISTRIBUTION 
MALES AND FEMALES 
 
Sex Distribution 
Gender N % 
Male 27 54% 
Female 23 46% 
Total 50 100% 
 
 
In our study population male predominates with 54% 
  
54%
46%
Gender
Male
Female
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TABLE: 3  
AMOUNT OF CONSUMPTION 
 
Amount of Consumption of PQ(ml) No % 
< 20 ml 6 12.0% 
20-50ml 31 62.0% 
50-150 ml 7 14.0% 
>150 ml 6 12.0% 
total 50 100.0% 
 
 
 
In our study, almost all the patients are exposed to paraquat poisoning 
by ingestion, amount of consumption paraquat 20-50 ml 62%, less than 20 ml 
12%. Because predictor of prognosis depends amount of consumption. 
12%
62%
14%
12%
Amount of Consumption of PQ(ml)
< 20 ml
20-50 ml
50-150 ml
>150 ml
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TABLE: 4 FREQUENCY OF SUBSTANCE USED 
FREQUENCY OF SUBSTANCE USED No % 
HERAQUAT 24% 7 14.0% 
AVAST24% 15 30.0% 
SWAT 24% 14 28.0% 
KAPIQ 24% 14 28.0% 
Total 50 100.0% 
 
 
 
Paraquat Dichloride 24% Herbicide (Weedkiller), is extensively to 
prevent the unwanted plant growth and to control of common pest on crops, in 
our study population most of the patients consumed 24% paraquat dichloride. 
  
14%
30%
28%
28%
FREQUENCY OF SUBSTANCE USED
HERAQUAT 24%
AVAST24%
SWAT 24%
KAPIQ 24%
TIME OF ARRIVAL TO THE HOSPITAL
Distribution of Time 
and Reaching the Hospital
< 6 Hrs
6
> 24Hrs
 
 
The severity of poisoning makes the patients seeking the health care 
centre earlier, 76% patients arrived to th
 
 
 
Distribution of Time between PQ 
ingestion and Reaching the Hospital  
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TABLE: 5  
 
between PQ ingestion 
 
No 
 4 
-24 Hrs 38 
 8 
Total 50 
e hospital 6- 24 hrs. 
8%
76%
16%
% 
8.0% 
76.0% 
16.0% 
100.0% 
 
< 6 Hrs
6-24 Hrs
> 24Hrs
TABLE: 6 URINE SODIUM DITHIONITE TEST
SEMI 
Urine Sodium Dithionite Test
Barely Distinguishable Blue (1+)
Light Blue (2+)
Dark Blue (3+)
Black (4+)
Total
 
 All cases of acute paraquat poisoning admitted 
irrespective of age and sex showing positive urine sodium dithionite
included in this study.40
dark blue colour, (24%) Barely blue. 
36%
Urine Sodium Dithionite Test
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QUANTITATIVE TEST 
 No 
 12 
 20 
 18 
 0 
 
50 100.0%
in our
% of people’s shows light blue, 36% people shows 
 
24%
40%
0%
Barely Distinguishable Blue 
(1+)
Light Blue (2+)
Dark Blue (3+)
Black (4+)
 
% 
24.0% 
40.0% 
36.0% 
0.0% 
 
 
 hospital 
 test 
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TABLE: 7  
ABG ANALYSES 
POTENTIAL OF HYDROGEN 
ABG ANALYSIS N Mean 
Std. 
Dev
iatio
n 
Std. 
Err
or 
95% Confidence 
Interval for Mean 
Min Maxi
mum 
  
Lower 
Bound 
Upper 
Bound 
F 
VALU
E 
P 
VAL
UE 
PH 
ON 
ADMISSI
ON 
50 7.21 0.22 0.03 7.14 7.27 6.7 7.8 
6.678* 0.002 24 HRS 45 7.10 0.25 0.04 7.03 7.18 6.2 7.4 
48 HRS 32 6.99 0.33 0.06 6.87 7.11 6.2 7.4 
 
*Significant 
 
If the pH is below 7.40, the primary disorder is presumed to be an 
acidosis, If the pH is above 7.40, the primary disorder is presumed to be an 
alkalosis, in this study there is a significant correlation of ph level on 
admission, 24hrs, 48hrs 
 
7.21
7.10
6.99
6.85
6.90
6.95
7.00
7.05
7.10
7.15
7.20
7.25
ON ADMISSION 24 HRS 48 HRS
PH
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TABLE NO - 8 
PARTIAL PRESSURE OF ARTERIAL OXYGEN 
 
 
 
 
Pa02 partial pressure of oxygen, normal value of Pao2 irrespective of 
age is greater than 80 mm of hg/10.6kpa, in this study there is significant 
correlation of pao2 on admission, 24 hrs, and 48hrs 
  
 
92.06
201.2
139.77
0
50
100
150
200
250
ON ADMISSION 24 HRS 48 HRS
PaO2
ABG ANALYSIS N Mean 
Std. 
Devi
ation 
Std. 
Erro
r 
95% Confidence 
Interval for Mean 
Min 
Ma
xi
mu
m 
Lower 
Bound 
Upper 
Bound 
F 
VALU
E 
P 
VALU
E 
PAO2 
ON 
ADMISSI
ON 
50 92.06 38.13 5.39 81.22 102.89 68.5 
35
0 
28.458
** 
P<0.00
1 24 HRS 45 201.20 
102.
89 
15.3
4 170.29 232.11 62 
37
0 
48 HRS 32 139.77 
50.3
1 8.89 121.63 157.90 60 
25
0 
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TABLE NO - 9 
PARTIAL PRESSURE OF ARTERIAL CARBON DIOXIDE 
 
 
 
In ABG high Paco2 levels indicate respiratory acidosis (a PaCO2 greater 
than 45 mm Hg) in our study Paco2 level significant correlation on admission, 
24hrs, and 48 hrs. 
 
46.63
44.92
43.63
42
42.5
43
43.5
44
44.5
45
45.5
46
46.5
47
ON ADMISSION 24 HRS 48 HRS
PaCO2
ABG ANALYSIS N Mean 
Std. 
Dev
iatio
n 
Std. 
Err
or 
95% Confidence 
Interval for 
Mean Min 
Ma
xi
mu
m 
  
Lower 
Bound 
Upper 
Bound 
F 
VALU
E 
P 
VALU
E 
PACO2 
ON 
ADMISSI
ON 
50 46.63 3.97 0.56 45.50 47.76 38 60 
5.679* 0.004 24 HRS 45 44.92 3.79 0.57 43.78 46.06 38 55 
48 HRS 32 43.63 4.45 0.79 42.02 45.23 36 55 
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TABLE NO-10 
BICARBONATE 
 
 
 
In ABG elevated bicarbanate levels indicate metabolic acidosis 
(a bicarbonate level less than 24 mEq/L); in our study there is no significant 
correlation on admission, 24hrs, and 48hrs 
 
 
21.59
19.81
19.59
18.5
19
19.5
20
20.5
21
21.5
22
ON ADMISSION 24 HRS 48 HRS
HCO3
 ABG ANALYSIS N Mean 
Std. 
Devi
ation 
Std. 
Erro
r 
95% Confidence 
Interval for Mean 
Min 
Ma
xi
mu
m 
    
Lower 
Bound 
Upper 
Bound 
F 
VALU
E 
P 
VALU
E 
HCO3 
ON 
ADMISSI
ON 
50 21.59 3.16 0.45 20.69 22.48 12 26 
3.042 0.051 
24 HRS 45 19.81 4.54 0.68 18.45 21.18 12 38 
48 HRS 32 19.59 4.99 0.88 17.80 21.39 10 32 
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TABLE NO-11 
PaO2/FIO2 Ratio of Partial Pressure Arterial Oxygen and Fraction of 
Inspired Oxygen 
 
 
 
 
Low Pao2/fio2 indicate the degree of lung injury, in our study reveals 
there is a significant correlation with admission, 24 hrs, 48 hrs 
 
306
258.83
244.75
0
50
100
150
200
250
300
350
ON ADMISSION 24 HRS 48 HRS
PAO2/FIO2
ABG ANALYSIS N Mean 
Std. 
Devi
ation 
Std. 
Erro
r 
95% Confidence 
Interval for Mean 
Min 
Max
imu
m 
  
Lower 
Bound 
Upper 
Bound 
F 
VAL
UE 
P 
VALU
E 
PAO2/FI
O2 
ON 
ADMISSI
ON 
50 306.00 
88.3
6 
12.5
0 280.89 331.11 100 430 
3.757
* 
0.026 24 HRS 45 258.83 
110.
42 
16.4
6 225.65 292.00 100 440 
48 HRS 32 244.75 
133.
04 
23.5
2 196.79 292.72 100 420 
PREDICTOR OF PROGNOSIS BY LEUCOCYTES COUNT ON TIME 
Hematological 
Parameters 
N Mean
LEUCOCY
TEScumm 
ON 
ADMISS
ION 
50 11842.00
24 HRS 45 17473.11
48 HRS 32 11898.00
 
Our study reveals leucocytosis
level indicate the predictor
 
 
 
0
2000
4000
6000
8000
10000
12000
14000
16000
18000
ON ADMISSION
11842
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TABLE NO - 12 
FREQUENCY ANALYSIS 
 
Std. 
Deviatio
n 
Std. 
Error 
95% Confidence 
Interval for Mean 
Lower 
Bound 
Upper 
Bound 
 5640.35 797.67 10239.03 13444.97 
 28565.83 4258.34 8890.99 26055.24 
 6062.66 1106.89 9634.17 14161.83 
 on admission, 24hrs, 48hrs, increased
 of prognosis in ARDS patients 
24 HRS 48 HRS
17473.11
11898
LEUCOCYTES/cumm
Minimu
m 
Maximum 
3500.00 22000.00 
3650.00 200000.00 
3500.00 20000.00 
 
 
PREDICTOR OF PROGNOSIS BY NEUTROPHIL COUNT ON TIME 
 
 
 
Our study reveals
mean value at 48 hrs 4683.03
 
 
4550
4600
4650
4700
4750
4800
4850
4900
4950
ON ADMISSION
4758.6
Hematological 
Parameters N Mean
NEUTRO
PHIL/cum
m 
ON 
ADMIS
SION 
50 4758.60
24 HRS 45 4907.11
48 HRS 32 4683.03
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TABLE NO - 13 
FREQUENCY ANALYSIS 
 neutrophil count on admission, 24 hrs, and 48hrs
 
24 HRS 48 HRS
4907.11
4683.03
NEUTROPHIL/cumm
 
Std. 
Deviati
on 
Std. 
Error 
95% Confidence 
Interval for Mean 
Lower 
Bound 
Upper 
Bound 
 940.26 132.97 4491.38 5025.82 
 
1264.9
6 188.57 4527.08 5287.15 
 
1024.0
3 186.96 4300.66 5065.41 
 
, 
Minim
um 
Maximu
m 
3330.0
0 8200.00 
2500.0
0 9500.00 
3100.0
0 8500.00 
 PREDICTOR OF PROGNOSIS BY LYMPHOCYTE COUNT ON TIME 
 
 
Our study reveals Lymphocyte
value at 48 hrs 1582.33
 
1250
1300
1350
1400
1450
1500
1550
1600
ON ADMISSION
1390.2
Hematological 
Parameters 
N Mean
LYMPHO
CYTEcu
mm 
ON 
ADMIS
SION 
50 1390.20
24 HRS 45 1385.82
48 HRS 32 1582.33
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TABLE NO-14 
FREQUENCY ANALYSIS 
 count on adm, 24hrs, 48hrs, and mean
 
24 HRS 48 HRS
1385.82
1582.33
LYMPHOCYTE/cumm
 
Std. 
Deviati
on 
Std. 
Error 
95% Confidence 
Interval for Mean 
Lower 
Bound 
Upper 
Bound 
 523.37 74.02 1241.46 1538.94 
 580.60 86.55 1211.39 1560.25 
 719.02 131.27 1313.85 1850.82 
 
 
Minim
um 
Maximu
m 
900.00 2500.00 
820.00 3110.00 
800.00 3000.00 
PREDICTOR OF PROGNOSIS BY PLATELET COUNT ON TIME 
 
 
Our study shows thrombocyto
as an independent risk factor for 
 
 
96000
98000
100000
102000
104000
106000
108000
110000
112000
114000
ON ADMISSION
111840
Hematological 
Parameters N Mean
PLATELE
Tcumm 
ON 
ADMIS
SION 
50 111840.00
24 HRS 45 102845.33
48 HRS 32 112666.67
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TABLE NO - 15 
FREQUENCY ANALYSIS 
penia on adm, 24hrs, 48hrs.it
mortality. 
24 HRS 48 HRS
102845.33
112666.67
PLATELET/cumm
 
Std. 
Deviati
on 
Std. 
Error 
95% Confidence 
Interval for Mean 
Lower 
Bound 
Upper 
Bound 
 
38261.
91 5411.05 
100966.
09 122713.91 
 
51208.
19 7633.67 
87460.6
9 118229.98 
 
50800.
71 9274.90 
93697.3
7 131635.97 
 
 recognised 
Mini
mum 
Maximum 
5500
0.00 180000.00 
4500
0.00 201040.00 
4500
0.00 180000.00 
 Our study reveals
48 hrs 8.42   
 
8
8.2
8.4
8.6
8.8
9
9.2
ON ADMISSION
9.16
Hematological 
Parameters N Mean
HB g/dl 
ON 
ADMI
SSIO
N 
50 9.16
24 
HRS 45 9.00
48 
HRS 32 8.42
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TABLE NO-16 
HEMOGLOBIN (Hb g/dl) 
 
 hemoglobin on adm, 24hrs, 48hrs, and mean
      
24 HRS 48 HRS
9
8.42
HB g/dl
 
Std. 
Devia
tion 
Std. 
Error 
95% 
Confidence 
Interval for 
Mean 
Lower 
Bound 
Upper 
Bound 
 0.67 0.09 8.97 9.35 
 0.51 0.08 8.84 9.15 
 2.10 0.39 7.62 9.21 
 
 value at 
Mini
mum 
Maxim
um 
8.00 12.00 
8.10 11.00 
0.90 9.60 
 PREDICTOR OF PROGNOSIS BY 
NEUTROPHILLYMPHOCYTE RATIO
 
NLR is a biomarker of 
ratio on adm, 24hrs, and 48hrs, used
patients 
3.5
3.6
3.7
3.8
3.9
4
4.1
4.2
ON ADMISSION
3.96
NLR Ratio Neutrophil / Lymphocyte Ratio
Hematological 
Parameters N Mean
NLR_Rat
io_Neutr
ophilLy
mphocyt
e_Ratio 
ON 
ADMI
SSION 
50 3.96
24 
HRS 45 4.18
48 
HRS 32 3.79
56 
TABLE NO-17 
NLR RATIO 
ON TIME FREQUENCY 
ANALYSIS 
inflammation, inour study shows increased NLR 
 for predictor of prognosis in ARDS 
24 HRS 48 HRS
4.18
3.79
 
Std. 
Deviat
ion 
Std. 
Error 
95% Confidence 
Interval for Mean 
Lower 
Bound 
Upper 
Bound 
 1.67 0.24 3.48 4.43 
 1.87 0.28 3.61 4.74 
 2.05 0.37 3.02 4.55 
 
Minim
um 
Maximu
m 
1.43 8.00 
1.05 7.60 
1.17 7.08 
  
Acute kidney injury is usually based on measurements of blood urea 
nitrogen and serum creatinine.
24 hrs, 48 hrs, increased serum urea 
 
74
76
78
80
82
84
86
88
90
92
94
ON ADMISSION
81.6
Hematological 
Parameters N Mean
UREA_
mgdl 
ON 
ADMI
SSIO
N 
50 81.60
24 
HRS 45 93.47
48 
HRS 32 86.43
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TABLE NO-18 
SERUM UREA 
 In our study increased serum urea on adm,
associated with reduced gfr & renal injury.
24 HRS 48 HRS
93.47
86.43
UREA mg/dl
 
Std. 
Devia
tion 
Std. 
Error 
95% Confidence 
Interval for 
Mean 
Lower 
Bound 
Upper 
Bound 
 41.02 5.80 69.94 93.26 
 40.90 6.10 81.18 105.75 
 51.23 9.35 67.30 105.56 
 
  
 
Mini
mum 
Maxim
um 
18.00 150.00 
22.00 150.00 
23.00 210.00 
  
Our study shows increased serum creatinine on 
level indicates renal damage
 
 
0
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1
1.5
2
2.5
3
3.5
4
4.5
ON ADMISSION
3.21
SERUM CREATININE mg/dl
Hematological 
Parameters N 
SERUM
CREATI
NINEmg
dl 
ON 
ADMIS
SION 
50 
24 HRS 45 
48 HRS 32 
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TABLE NO-19 
SERUM CREATININE 
adm, 24hrs, 48hrs, high
.  
24 HRS 48 HRS
4.22
4.05
Mea
n 
Std. 
Devia
tion 
Std. 
Error 
95% Confidence 
Interval for 
Mean 
Lower 
Bound 
Upper 
Bound 
3.21 2.19 0.31 2.59 3.83 
4.22 2.60 0.39 3.44 5.00 
4.05 2.97 0.54 2.94 5.16 
 
 
Mini
mum 
Maxim
um 
0.60 8.30 
0.40 8.00 
0.60 8.50 
 Our study shows increased serum bilirubin on adm, 24hrs
indicates liver damage. 
 
0
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1
1.5
2
2.5
3
3.5
4
4.5
ON ADMISSION
3.49
Hematological 
Parameters N Mean
SERUM 
BILIRUB
INmgdl 
ON 
ADMI
SSIO
N 
50 
24 
HRS 45 
48 
HRS 32 
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TABLE NO - 20 
SERUM BILIRUBIN 
 
 
24 HRS 48 HRS
4.25
3.79
SERUM BILIRUBIN mg/dl
 
Std. 
Devia
tion 
Std. 
Error 
95% Confidence 
Interval for 
Mean 
Lower 
Bound 
Upper 
Bound 
3.49 2.46 0.35 2.79 4.18 
4.25 2.71 0.40 3.44 5.07 
3.79 2.92 0.53 2.70 4.88 
 
, 48hrs, it 
Mini
mum 
Maxim
um 
0.60 7.60 
0.00 8.00 
0.60 9.00 
  
 
Our study plasma CRP level increased on adm
marker for inflammation, produced in the liver will 
inflammation, classified 
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5.97
Hematological 
Parameters N Mean
CRPmgd
l 
ON 
ADMI
SSION 
50 5.97
24 
HRS 45 7.57
48 
HRS 32 7.32
60 
TABLE NO -21 
C-REACTIVE PROTEIN 
, 24hrs, 48hrs, CRP
rise in response to 
as acute phase reactant 
24 HRS 48 HRS
7.57
7.32
CRP mg/dl
 
Std. 
Deviat
ion 
Std. 
Error 
95% Confidence 
Interval for Mean 
Lower 
Bound 
Upper 
Bound 
 2.42 0.34 5.28 6.66 
 2.96 0.44 6.68 8.46 
 3.38 0.61 6.08 8.56 
 
 is the 
Minim
um 
Maximu
m 
3.00 12.00 
2.00 12.00 
0.00 12.00 
MEAN ARTERIAL PRESSURE
 
MAP is a better 
sepsis; vasopressors are titr
72.33 
 
 
 
64
66
68
70
72
74
76
ON ADMISSION
74.82
Hematological 
Parameters N Mean
HYPOTE
NSIONM
AP 
ON 
ADMIS
SION 
50 74.82
24 HRS 45 67.80
48 HRS 32 72.33
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TABLE NO-22 
 
 
indicator of perfusion to vital organs, in patients with 
ated based on this, mean value of MAP at 48 hrs 
24 HRS 48 HRS
67.8
72.33
HYPOTENSION (MAP)
 
Std. 
Deviati
on 
Std. 
Error 
95% Confidence 
Interval for Mean 
Lower 
Bound 
Upper 
Bound 
 16.14 2.28 70.23 79.41 
 16.28 2.43 62.91 72.69 
 16.48 3.01 66.18 78.49 
 
Minim
um 
Maximu
m 
50.00 98.00 
50.00 96.00 
50.00 96.00 
PREDICTOR OF PROGNOSIS BY SOFA SCORE
Predictor of Prognosis by SOFA SCORE
SCORE ON ADMISSION 
 
0 to 6 
07 to 12 
13 to 24 
total 
Chi-square statistics =45.8284**
Sequential organ failure assessment score 
morbidity and mortality
the clinical outcomes of critically ill patients.
correlation between on admission
 
0%
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ON ADMISSION 
(50)
32%
60%
8%
62 
TABLE NO-23 
 
(50) 24 Hrs (45) 48 Hrs (32)
No % No % No 
16 32% 14 31% 13 
30 60% 2 4% 9 
4 8% 29 64% 10 
50 100% 45 100% 32 
the p-value < 0.001 
estimating the risk of 
, and predict the early onset of ARDS, and
 in this study there is a 
, 24hrs, and 48hrs 
 
24 Hrs (45) 48 Hrs (32)
31%
41%
4%
28%
65%
31%
 
 
% 
41% 
28% 
31% 
100% 
 
 predicting 
significant 
13 to 24
07 to 12
0 to 6
PREDICTOR OF PROGNOSIS BY ACUTE KIDNEY INJURY SCORE
Predictor of Prognosis by ACUTE KIDNEY INJURY SCORE
SCORE ON ADMISSION 
STAGE 
0 
1 
2 
3 
total 
 
Chi-square statistics = 27.041**
Acute kidney injury is the common complication of acute paraquat 
poisoning, in our study 
on adm, 24hrs, and 48hrs
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
ON ADMISSION 
(50)
30%
54%
8%
8%
63 
TABLE NO-24 
(50) 24 Hrs (45) 48 Hrs (32)
No % No % No 
15 30% 14 31.1% 11 
27 54% 9 20.0% 3 
4 8% 10 22.2% 6 
4 8% 12 26.7% 12 
50 100% 45 100% 32 
the p<0 .001 
reveals there is significant correlation of AKIN Score 
. 
 
24 Hrs (45) 48 Hrs (32)
31% 34%
20% 9%
22%
19%
27%
38%
 
 
 
% 
34% 
9% 
19% 
38% 
100% 
 
Stage 3
Stage 2
Stage 1
Stage 0
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TABLE NO-25 
REQUIREMENT OF MECHANICAL VENTILATION 
Independent t test  for MV at Admission 
admmv N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
t  value p value 
sofa@adm 
Yes 8 11.3750 1.59799 .56497 
2.727** .009 
No 42 7.6905 3.73179 .57583 
Independent t test  for MV at  24 HRS 
mv24hrs N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
t  value p value 
sofa@24hrs 
Yes 9 17.3333 2.73861 .91287 
2.411* .020 
No 36 11.7778 6.72781 1.12130 
Independent t test  for MV at  48 HRS 
mv48hrs N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
t  value p value 
sofa@48hrs 
Yes 12 11.6667 2.80692 .81029 
2.932* .006 
No 20 7.2500 4.72257 1.05600 
 
  
In our study reveals signi
mechical ventilation. 
 
 
0
2
4
6
8
10
12
14
16
18
SOFA AT 
ADMISSION
11.38
7.69
65 
 
 
 
TABLE NO-25 
ficant association with SOFA SCORE and 
 
SOFA AT 24 HRS
SOFA AT 48 HRS
17.33
11.67
11.78
7.25
 
MV YES
MV NO
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TABLE NO-26 
REQUIREMENT OF HEMODIALYSIS 
Independent t test  for HD  at Admission 
admhd N Mean 
Std. 
Deviation 
Std. 
Error 
Mean t  value 
p 
value 
sofa@ad
m 
Yes 8 11.3750 1.59799 .56497 2.727*
* 
.009 
No 42 7.6905 3.73179 .57583 
Independent t test  for  HD at  24 HRS 
HD 24hrs N Mean 
Std. 
Deviatio
n 
Std. 
Error 
Mean t  value 
p 
value 
sofa@24hr
s 
Ye
s 
18 
14.888
9 
5.13224 
1.2096
8 
1.719 .093 
No 
27 
11.555
6 
7.06744 
1.3601
3 
Independent t test  for  HD at  48 HRS 
HD 48 hrs N Mean 
Std. 
Deviatio
n 
Std. 
Error 
Mean t  value 
p 
value 
sofa@48hr
s 
Ye
s 
10 
12.300
0 
1.56702 .49554 
3.205*
* 
.003 
No 
22 7.3636 4.71619 
1.0054
9 
 
 
 
 
 
  
Our study reveals th
and hemodialysis at 48 hrs
 
 
0
2
4
6
8
10
12
14
16
SOFA AT ADMISSION
11.38
7.69
67 
 
 
 
TABLE NO-26 
ere is significant association with SOFA SCORE 
 
 
SOFA AT 24 HRS
SOFA AT 48 HRS
14.89
12.3
11.56
7.36
 
HD YES
HD NO
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TABLE NO-27 (A)QUANTEM OF EXPOSURE AND SOFA SCORE 
 N
 
M
ea
n
 
St
d.
 
D
ev
ia
tio
n
 
St
d.
 
Er
ro
r 
95
%
 
Co
n
fid
en
ce
 
In
te
rv
al
 
fo
r 
M
ea
n
 
M
in
im
u
m
 
M
a
xi
m
u
m
 
A
N
O
V
A
 
TE
ST
 
 
Lower 
Bound 
Upper 
Bound 
sofa@adm Up to 20 ml 6 2.67 1.03 0.42 1.58 3.75 1.00 4.00 
9.311** 
21ml-50 ml 31 8.42 3.52 0.63 7.13 9.71 3.00 14.00 
51ml-150ml 7 10.29 1.70 0.64 8.71 11.86 9.00 13.00 
Above 150 ml 6 10.83 2.40 0.98 8.31 13.35 6.00 12.00 
Total 50 8.28 3.73 0.53 7.22 9.34 1.00 14.00 
sofa@24hrs Up to 20 ml 6 3.17 0.41 0.17 2.74 3.60 3.00 4.00 
16.741** 
21ml-50 ml 31 13.65 6.03 1.08 11.44 15.86 3.00 21.00 
51ml-150ml 7 17.86 1.77 0.67 16.22 19.50 15.00 21.00 
Above 150 ml 6 15.17 5.31 2.17 -3.40 7.74 0.00 13.00 
Total 50 11.60 7.30 1.03 9.52 13.68 0.00 21.00 
sofa@48hrs Up to 20 ml 5 3.20 0.45 0.20 2.64 3.76 3.00 4.00 
12.482** 
21ml-50 ml 27 9.96 4.22 0.81 8.29 11.63 3.00 14.00 
51ml-150ml 0 
       
Above 150 ml 0 
       
Total 32 8.91 4.60 0.81 7.25 10.57 3.00 14.00 
           
ANOVA TEST **SIGNIFICANT 
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TABLE NO-27 
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0
2
4
6
8
10
12
Up to 20 ml 21ml-50 ml 51ml-150 ml Above 150 ml
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TABLE NO-27 (B) 
QUANTEM OF EXPOSURE AND SOFA SCORE 
 
 
 
Our study shows there is a significant correlation with quantum of 
exposure and SOFA SCORE 
3.17
13.65
17.86
15.17
0
2
4
6
8
10
12
14
16
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Up to 20 ml 21ml-50 ml 51ml-150 ml Above 150 ml
SOFA SCORE AT 24 HRS
3.2
9.96
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Up to 20 ml 21ml-50 ml
SOFA SCORE AT 48 HRS
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TABLE NO-28 
DURATION OF STAY IN THE HOSPITAL 
 
DURATION OF STAY IN THE HOSPITAL 
TIME NO % 
   
24 HRS 5 10% 
48 HRS 13 26% 
7 DAYS 14 28% 
8 TO 15 DAYS 10 20% 
> 15 DAYS 8 16% 
TOTAL 50 100% 
 
 
 
PQ poisoning has high morbidity and mortality, duration of stay 
depends amount of consumption, complications, in our study reveals 28% were 
stayed  >15 days 
 
 
 
0
10%
26%
28%
20%
16%
DURATION OF STAY IN THE HOSPITAL
24 HRS
48 HRS
7 DAYS
8 TO 15 DAYS
> 15 DAYS
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TABLE NO-29 
CLINICAL CHARACTERISTICS OF PQ PATIENTS WITH ARDS 
AND NON-ARDS AT 48HRS 
  N Mean 
Std. 
Deviatio
n 
Std. 
Error 
Mean 
 T 
VALU
E 
P 
VALU
E 
SOFA  SCORE NARDS 13 3.10 0.50 0.14 10.912 P<0.00
1 
 ARDS 19 17.20 5.60 1.28 
AKIN SCORE NARDS 13 13.00 2.26 0.63 6.061 P<0.00
1 ARDS 19 19.00 3.34 0.77 
LEUCOCYTEScum
m 
NARDS 13 6533.85 3677.71 1020.0
1 
6.749 P<0.00
1 
ARDS 19 16000.00 3901.12 946.16 
NEUTROPHILcum
m 
NARDS 13 3945.46 492.25 136.52 4.415 P<0.00
1 ARDS 19 5247.06 968.97 235.01 
LYMPHOCYTEcu
mm 
NARDS 13 2304.62 367.46 101.92 10.526 P<0.00
1 ARDS 19 1030.00 296.25 71.85 
PLATELETcumm NARDS 13 161692.31 14354.93 3981.3
4 
8.852 P<0.00
1 
ARDS 19 75176.47 32814.32 7958.6
4 
HBmgdl NARDS 13 7.65 3.01 0.84 1.841 0.077 
ARDS 19 9.04 0.20 0.05 
NLR_Ratio_Neutrop
hilLymphocyte_Rati
o 
NARDS 13 1.74 0.29 0.08 10.267 P<0.00
1 ARDS 19 5.35 1.24 0.30 
UREA_mgdl NARDS 13 35.23 8.06 2.24 10.268 P<0.00
1 ARDS 19 125.59 30.82 7.47 
SERUM_CREATIN
INEmgdl 
NARDS 13 1.00 0.22 0.06 11.941 P<0.00
1 ARDS 19 6.39 1.61 0.39 
SERUM_BILIRUBI
Nmgdl 
NARDS 13 0.90 0.20 0.05 9.828 P<0.00
1 ARDS 19 6.00 1.86 0.45 
CRP_mgdl NARDS 13 4.31 0.75 0.21 6.482 P<0.00
1 ARDS 19 9.59 2.85 0.69 
HYPOTENSIONM
AP 
NARDS 13 88.85 6.08 1.69 10.407 P<0.00
1 ARDS 19 59.71 8.56 2.08 
 
Our study ARDS has significant correlation of sofa, akin score, 
leucocyte count, lymphocyte count, platelet count, compared with non ARDS 
and NON ARDS 
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TABLE NO-30 
REQUIREMENT OF PULSE THERAPY 
Independent t test  for Pulse therapy at Admission 
admmv N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
t  value p 
value 
sofa@adm 
Yes 9 10.4444 2.06828 .68943 
2.884** 
.009 
No 41 7.8049 3.85499 .60205 
 
Independent t test  for Pulse therapy at  24 HRS 
mv24hrs N Mean 
Std. 
Deviatio
n 
Std. 
Error 
Mean 
t  
value 
p 
value 
sofa@24hr
s 
Ye
s 
10 
15.300
0 
6.65081 
2.1031
7 
1.355 
.187 
(ns) 
No 35 
12.200
0 
6.40221 
1.0821
7 
 
Independent t test  for Pulse therapy at  48 HRS 
mv48hrs N Mean 
Std. 
Deviatio
n 
Std. Error 
Mean 
t  
value 
p 
value 
sofa@ 
48hrs 
Ye
s 
16 
11.375
0 
3.36403 .84101 3.560
* 
.001 
No 16 6.4375 4.41163 1.10291 
 
 
 
 Our study shows signi
therapy at 48 hrs. 
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TABLE NO-30 
ficant correlation with SOFA SCORE and pulse 
 
SOFA AT 24 HRS
SOFA AT 48 HRS
15.30
11.38
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PT  YES
PT  NO
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TABLE NO-31 
COMPLICATION OF PQ POISOING 
 
COMPLICATION OF PQ POISOING 
CAUSE NO % 
METABOLIC ACIDOSIS 4 8.3% 
AKI 13 27% 
ARDS 19 39.5% 
MODS 12 25% 
TOTAL 48 99.8% 
 
  
  
 
COMPLICATION OF PQ POISOING
 
Paraquat causes high fatality due to 
liver injury, multi organ 
about 39.5% 
 
39.5
25
76 
TABLE NO-31 
 
ARDS, lung fibrosis, renal
failure, in our study shows predominantly ARDS 
 
8.3
27.0
CAUSES
METABOLIC ACIDOSIS
AKI
ARDS
MODS
 
 injury, 
PERCENTAGE OF MOTALITY
PERCENTAGE OF MOTALITY
TIME
<24 HRS
48 HRS
3 TO 7 DAYS
8 TO 14 DAYS
> 15 DAYS
TOTAL
 
Pq mortality depends upon the amount of consumption,
complications. It causes renal and hepatic failure,
fibrosis, shock, convulsions,
to 7 days(29.1%) 
 
20.8
77 
TABLE NO-32 
 
 
 NO 
 5 
 13 
 14 
 10 
 6 
 48 
 pulmonoruy edema,
 multiorgan failure, in our study predominantly at 3 
0
10.4
27.0
29.1
12.5
MORTALITY
<24HRS
48 HRS
3 TO 7 DAYS
8 TO 14 DAYS
> 15 DAYS
10.4% 
27.0% 
29.1% 
20.8% 
12.5% 
99.9% 
 
 and its 
 and lung 
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DISCUSSION 
Comprehensive analysis of 50 cases of acute Paraquat poisoning. 
EPIDEMIOLOGY OF PARAQUAT POISOINING 
AGE DISTRIBUTION: 
In this study, the paraquat poisoning was most prevalent in the age 
group 21 – 50 years. 33 cases out of 50 were below the age of 50years. Another 
study from china the mean age of patients was 32 years This young age group 
affected by exposure and also in terms of procurement and productivity. This 
study throws light on the target age group by improving the management 
protocol and decreasing the mortality. 
SEX DISTRIBUTION: 
    In this study, the paraquat poisoning was most prevalent in the age 
group 21 – 50 years. Female intoxication was more.  In Southern part of India, 
males are actively involved in spraying fertilizers and pest. The retrospective 
cohort study included 202 patients with PQ poisoning were conducted in the 
emergency department (ED) from January 2010 to December 2015 at the First 
Affiliated Hospital, Anhui Medical University (Hefei, China). 202 patients 
were included in the analysis. . In brief, the median age of patients was 32.00 
(16.00–84.00) years, and 126 (62.38%) of the 202 patients were female. 
ROUTE OF EXPOSURE: 
In our study, most of the cases occurred due to ingestion (100%) 
attempting suicide. 
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FREQUENCY OF EXPOSED: 
The common paraquat compounds abused in our series are Paraquat 
dichloride 24% 
URINE SODIUM DITHIONITE TEST 
           Urine test was used as paraquat screening test (semi quantitative test). 
Confirmatory diagnosis of paraquat was only possible by checking blood 
paraquat concentrations. serum PQ concentrations is not available in all 
hospitals, the amount of ingestion very difficult to estimate particularly in 
patients presents with confusional state. For this reason we sought to identify 
simple parameter for estimating prognosis of acute paraquat poisoning 
QUANTAM OFEXPOSURE 
Amount of paraquat ingestion clearly significant with motality and 
SOFA score and outcome of the patient. 
PREDICTOR OF PROGNOSIS BY SOFA SCORE 
SOFA scoring was much reliable that it correlated clearly with the 
duration of Hospital stay, development of complications, quantum of exposure, 
mechanical ventilation, pulse therapy, hemodialysis, In spite of effective 
treatment5 cases were died<24 hrs,13 cases were died <48 hrs, hence we 
excluded 5 patients from 24 hrs,13 patients from  48 hrs 
LABORATORY CORRELATES: 
ARDS patients has significant correlation of SOFA SCORE,AKIN 
SCORE and leucocyte count, platelet count, increase NLR ratio compared with 
non ARDS patients 
80 
 
Hence, it is our opinion from the study SOFA SCORE, AKIN SCORE 
predict the early development of ARDS, and hence we can start the pulse 
therapy as early as possible thus reducing morbidity and mortality 
 
 
 
  
  
 
 
 
CONCLUSION 
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CONCLUSION 
In summary, the present study shows that acute pq poisoning can cause 
leucocytosis, throbocytopenia. high NLR ratio, have excellent predictor of 
prognosis in acute pq poisoning .the analytical study  results indicate that 
SOFA SCORE,AKIN ACORE at 48hrs are significantly associated with 
mechanical ventilation, hemodialysis, pulse therapy, ARDS has significant 
correlation of  leucocyte count, lymphocyte count, platelet count, NLR ratio 
with non ARDS patients 
There is no specific antidote available for paraquat poisoning. increased 
awareness of the clinician and availability of the laboratory diagnostic methods 
will definitely help in successful management of paraquat poisoning 
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RECOMMENDATIONS 
To eliminate paraquat from the blood and tissue is hemoperfusion with 
activated charcoal; it has to be performed about 8h/d over a period of  
2-3 weeks. These measures to reduce   the mortality of paraquat poisoning 
Antioxidants such as acetylcysteine and salicylate might be beneficial 
through free radical scavenging, anti inflammatory and NK-KB inhibitory 
actions. However the case fatality rate is very high in all centres in spite of 
effective treatment 
Of all  herbicides paraquat is the most serious and high mortality, ,in 
spite of early hemodialysis, steroids, and cyclophosphamide therapy ,it was 
ineffective in reducing the mortality rates, newer treatment like hemoperfusion 
may help to reduce the mortality in future. 
Personal protection: 
• Training and good educational skills; 
• Ability to apply complex label instructions; 
• Appropriate personal protective equipment; 
• Access to running water to shower after spraying herbicides and wash 
the clothes 
• Easy access to medical treatment 
• Better quality and well maintained spray equipment  
• Suitable storage facilities for herbicides and the means to dispose of 
containers. 
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Recognising that governments, especially in developing countries lack 
the capacity to regulate pesticides and restrict the availability of the more 
hazardous pesticide formulations. 
Methods of prevention to decrease ingestion or inhalation of the 
chemical: 
1. Avoid the places that you know use paraquat or herbicides 
2. In places known for pq usage, only drink bottled water and other  
pre-packaged beverages. 
3. If you have a doubt about food or drink has been in contact with 
paraquat, don’t consume it. 
4. If you work with paraquat, to read all chemical labels carefully, shower 
immediately after using the chemical. 
5. If you think you have come in contact with liquid paraquat, remove any 
clothes immediately& change the clothes 
6. Try to avoid touching the areas contaminated with  clothes, Wash off 
any pq from the skin with large amounts of soap and water.  
7. If you wear contact lenses, remove them after washing your hands and 
body thoroughly and dispose of them with the clothing. Wash your 
entire body with soap and water. 
 
If you believe you have been affected by PQ poisoning, seek immediate 
emergency medical attention. If you work regularly with paraquat and worry 
about contamination, make sure you know how to manage the problems. 
 
  
 
 
 
 
SUMMARY 
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SUMMARY 
Paraquat is easily available & inexpensive in many developing 
countries. Intentional or accidental ingestion is the major reason associated 
with pq poisoning, the mortality rate was still remains very high in spite of 
hemodalysis, pulse therapy, therefore reliable predictor of prognosis may be 
helpful to guide the treatment and future clinical research on antidotes and 
other therapy. Hence, we conducted a study with 50 patients in our poison 
centre, Rajiv Gandhi Government General Hospital, Chennai. 
 
We found that, SOFA SCORE, AKINSCORE predict the early onset of 
ARDS and amount of paraquat ingestion directly proportional to the morbidity 
and mortality, however further studies are needed to reduce the morbidity and 
mortality. More research is needed to determine the effectiveness of various 
treatments 
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INFORMATION SHEET 
We are conducting a study on "A STUDY OF HEMATOLOGICAL 
INDICES, ASSESSMENT SCORES AND PREDICTOR OF 
PROGNOSIS IN PATIENTS WITH ACUTE PARAQUAT 
POISONING",  among patients attending Rajiv Gandhi Government General 
Hospital, Chennai and for that your specimen may be valuable to us. 
The Purpose of the study of Acute Paraquat poisoning is to investigate 
the haematological indices, assessment scores and evaluates the predictor of 
prognosis, By using assessment scores we can predict the ARDS earlier to star 
pulse therapy as early as possible.  
We are selecting certain cases and if you are found eligible, we may be 
using your blood samples to do certain tests. 
The privacy of the patients in the research will be maintained throughout 
the study. In the event of any publication or presentation resulting from the 
research, no personally identifiable information will be shared. 
Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not result 
in any loss of benefits to which you are otherwise entitled. 
The results of the special study may be intimated to you at the end of the 
study period or during the study if anything is found abnormal which may aid 
in the management or treatment. 
 
Signature of Participant    Signature of Investigator 
Date : 
Place : 
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PATIENT CONSENT FORM 
Study Detail : “A STUDY OF HEMATOLOGICAL INDICES, 
ASSESSMENT SCORES AND PREDICTOR OF 
PROGNOSIS IN PATIENTS WITH ACUTE 
PARAQUAT POISONING” 
Study Centre : Rajiv Gandhi Government General Hospital, 
Chennai. 
Patient’s Name :  
Patient’s Age :  
Identification Number :  
Patient may check (√) these boxes 
a) I confirm that I have understood the purpose of procedure for the above 
study. I have the opportunity to ask question and all my questions and 
doubts have been answered to my complete satisfaction. 
 
b) I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time without giving reason, without my legal 
rights being affected. 
 
c) I understand that sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory authorities 
will not need my permission to look at my health records, both in 
respect of current study and any further research that may be conducted 
in relation to it, even if I withdraw from the study I agree to this access. 
However, I understand that my identity will not be revealed in any 
 
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information released to third parties or published, unless as required 
under the law. I agree not to restrict the use of any data or results that 
arise from this study. 
d) I agree to take part in the above study and to comply with the 
instructions given during the study and faithfully cooperate with the 
study team and to immediately inform the study staff if I suffer from 
any deterioration in my health or well being or any unexpected or 
unusual symptoms. 
 
e) I hereby consent to participate in this study.  
f) I hereby give permission to undergo detailed clinical examination and 
blood investigations as required. 
 
 
Signature of Investigator    Signature\thumb impression 
DR.AUSPAS.J  Patient Name and address 
 
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PROFORMA 
NAME : 
AGE/SEX  : 
IP No. : 
OCCUPATION : 
ADDRESS : 
PRESENT HISTORY : 
Time of consumption 
Amount of consumption 
Concentration of paraquat 
Vomiting, urine output, oral ulcers 
Shortness of breath 
PAST HISTORY:  
Hypertention, Diabetes, ckd, malignancy, chronic liver disease 
PERSONAL HISTORY:  
Alcoholic, smoker, reason for consumption (suicidal, homicidal) 
GENERAL EXAMINATION: 
GCS :     CVS  : 
PR :     RS : 
BP :     P/A  : 
CNS : 
Urine Sodium Dithionite Screening Test : 
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DEMOGRAPHY 
AGE(YRS)  
GENDER(MALE/FEMALE)  
AMOUNT OF CONSUMPTION(ML)  
 
ABG ANALYSIS 
ABG 
AT THE TIME OF 
ADMISSION 
48HRS AFTER 
CONSUMPTION 
PH   
PaO2   
Paco2   
HCO3   
Pao2/fio2   
   
 
SOFA SCORE 
At the time of Admission 48 Hours 
 
HEMATOLOGICAL PARAMETERS 
LEUCOCYTES(/cumm)  
NEUTROPHIL(/cumm)  
LYMPHOCYTE(/cumm)  
PLATELET(/cumm)  
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HB(g/dl)  
NLR RATIO 
(Neutrophil/Lymphocyte ratio) 
 
UREA(mg/dl)  
SERUM CREATININE(mg/dl) 
 
 
SERUM BILIRUBIN(mg/dl)  
CRP  
 
AKIN SCORING SYSTEM: 
Category Serum Cr. Criteria Urine Output Criteria 
Stage 1 
Increase in serum Cr of >0.3 mg/dL of 
increaseto >150% to 200% (1.5 to 2-fold) 
from baseline 
<0.5 mL/kg/h for 
 more than 6 h 
Stage 2 Increase in serum Cr to >200 
<0.5 mL/kg/h for  
more than 12 h 
Stage 3 
Increase in serum Cr to >300% (3-fold) 
from baseline (or serum Cr of >4.0 mg/dL 
with an acute increase of at least 0.5mg/Dl 
<0.3 mL/kg/h for 24 h or 
anuria more than12 h 
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SOFA SCORING SYSTEM 
 0 1 2 3 4 
PaO2/FiO2 >400 301-400 201-300 
101-200 
with 
respiratory 
support 
<100 with 
respiratory 
support 
Platelets 
(1000/µL) 
>150 101-150 51-100 21-50 <20 
Bilirubin (mg/dL) <1.2 1.2-1.9 2.0-5.9 6.0-11.9 >12.0 
Hypotension 
MAP>70 
mmHg 
MAP<70 
mmHg 
Dopamine 
5 or 
dobutamine 
(any dose)* 
Dopamine 
>5 or 
epi<0.1 or 
norepi<0.1* 
Dopamine 
>15 or 
epi>0.1 
GCS 15 13-14 10-12 6-9 <6 
Cr (mg/dL) or UO <1.2 1.2-1.9 2.0-3.4 
3.5-4.9 or 
<500 mL/d 
>5.0 or 
<200 
mL/d 
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Arterial Blood Gas Analysis 
S.NO NAME Time PH PaO2 PaCO2 HCO3 PaO2/FIO2 
1 Sujatha Adm 7.36 96 40 23 400 
    24Hrs 7.3 96 45 22 420 
    48Hrs 7.4 95 40.7 23 410 
                
2 Iyyappan Adm 7.3 80 48 22 389 
    24Hrs 7.4 95 45 22.6 396.4 
    48Hrs 7.3 98 38.5 23 412 
                
3 Dilli Babu Adm 7 85 52 24 400 
    24Hrs 6.8 360 48 18 350 
    48Hrs 6.2 190 48 13 120 
                
4 Loganathan Adm 7.1 86 50 23 250 
    24Hrs 6.7 350 47 20.2 120 
    48Hrs           
                
5 Menaka Adm 7.34 98 45 23 380 
    24Hrs 7.35 96 43 23.4 410 
    48Hrs 7.36 98 43.3 24 396.3 
                
6 Kumar Adm 7.2 96 42 23 390 
    24Hrs 7.3 95 45.6 20 410 
    48Hrs 7.3 95 45 25 420 
                
7 Masilamani Adm 7.1 84 48 25 310 
    24Hrs 6.7 280 45.6 22 220 
    48Hrs 6.5 156.6 45 10 150 
                
8 Mohana Adm 6.8 85 52.4 14 220 
    24Hrs           
    48Hrs           
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9 Baskaran Adm 7.4 95 50.5 23 350 
    24Hrs 7.2 350.3 48 20 220 
    48Hrs 6.8 250 42 18.8 160 
                
10 Arul Adm 7.3 90 45 23.3 397 
    24Hrs 7.4 96.5 40.4 24.4 440 
    48Hrs 7.3 97 38.8 23.4 410 
                
11 Rani Adm 6.8 96 45.5 16 350 
    24Hrs           
    48Hrs           
                
12 Ethiraj Adm 6.7 88 45.5 18 330 
    24Hrs           
    48Hrs           
                
13 Kannan Adm 7.4 84 51.3 23.3 380 
    24Hrs 6.8 360.8 48 18 350 
    48Hrs           
                
14 Jagan Adm 7 82 48.2 22 360 
    24Hrs           
    48Hrs           
                
15 Sharmila Adm 7.2 88 52 21 350 
    24Hrs 6.9 190.6 46 17.6 240 
    48Hrs 6.5 145 42 12.2 130 
                
16 Manjupriya Adm 7.4 90 56 24 300 
    24Hrs 7 350 45 20.6 240 
    48Hrs 6.8 120 40 16 180 
                
17 Asok Adm 7.8 95 45 24 350 
    24Hrs 7.4 350.5 50.2 14 250 
    48Hrs 6.8 220 48 15 150 
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18 Reena Adm 7 75 60 25 350 
    24Hrs 6.7 150 50 15 150 
    48Hrs           
                
19 Prasanna Adm 7.2 90 48 19 350 
    24Hrs 6.9 370 40 20 150 
    48Hrs 7 150 46 16 120 
                
20 Thiagu Adm 7 350 48 19 280 
    24hrs 7.4 250 50 18 200 
    48hrs           
                
21 Kamalanathan Adm 7.4 95 45 23 412 
    24hrs 7.3 96.6 44.4 14.6 430 
    48hrs 7.34 97.7 46 18 398.8 
                
22 Yuvaraj Adm 7.5 90.8 45.6 23.3 200 
    24hrs 7.4 250 44.3 24 220 
    48hrs 7 150 38 15.3 140 
                
23 Sowmiya Adm 7.4 95 45.5 24 430 
    24hrs 7.34 90.6 43.3 23.3 390.3 
    48hrs 7.35 97.7 39.9 23.3 398 
                
24 Subramani Adm 7.5 96 38 23 390 
    24hrs 7.34 95 40 18 150 
    48hrs 6.6 200 50 15 150 
                
25 Mohan Adm 6.9 88 46 16 200 
    24hrs 7 250 48 14 180 
    48hrs           
                
26 Guruvayi Adm 7.2 80 44 23 250 
    24hrs 7 250 46 18 280 
    48hrs 6.8 150 45 14 150 
                
27 Tirumalai Adm 7 82 48 18 220 
    24hrs 7.2 178 45 15 150 
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    48hrs           
                
28 Devi Adm 7.3 95 45.6 23.3 390 
    24hrs 7.4 96 40 20 390 
    48hrs 7.3 60 45 22 390 
                
29 Vijaya kumar Adm 6.9 75 50 12 100 
    24hrs           
    48hrs           
                
30 Reshma Adm 7.2 85.5 42 22 150 
    24hrs 7.1 75.5 45 18 230 
    48hrs 7.1 250 48.8 27 140 
                
31 Poornima Adm 7.31 98 45 23 390 
    24hrs 7.29 95.5 44.5 20 410 
    48hrs 7.3 94 38.5 21.1 399 
                
32 Pandian Adm 7.2 80 44 23 250 
    24hrs 7 250 46 18 280 
    48hrs 6.8 150 45 14 150 
                
33 Venkatesan Adm 7 82 48 18 220 
    24hrs 7.2 178 45 15 150 
    48hrs 6.8 150 47.5 13 130 
                
34 Yuvaraj Adm 7.3 75.5 48 23 230 
    24hrs 6.9 210.5 46.1 18.4 210.5 
    48hrs           
                
35 Sumathi Adm 7.6 68.5 46 18 150 
    24hrs 7.3 210 40 13.5 100 
    48hrs           
                
36 Saranya Adm 7.5 88.5 47.5 26 250 
    24hrs 6.9 330.6 45 38 210 
103 
 
    48hrs 7 210 47 22.5 150 
                
37 Velu Adm 7.35 95 47 23 390 
    24hrs 7.2 96 45.5 26 400 
    48hrs 7.3 95 40.5 23 380 
                
38 Vanmathi Adm 7.2 85 47 18 250 
    24hrs 7.1 290 48 20.5 280 
    48hrs 7 160 40.5 22.5 120 
                
39 Naveen kumar Adm 7.34 96.5 40.5 24 390 
    24hrs 7.29 95 41 18.6 410 
    48hrs 7.3 96 42.5 23.9 388 
                
40 Dillibabu Adm 6.9 75.5 48.5 23.5 290 
    24hrs 6.2 250 50 27.5 160 
    48hrs           
                
41 Anjali Adm 7.17 86.5 44.5 23.6 250 
    24hrs 7 130.5 45.6 18.5 120 
    48hrs           
                
42 Leela Adm 7.35 95 40.5 23 390 
    24hrs 7 160 55 16 150 
    48hrs 6.9 150 52 18 120 
                
43 Balamurugan Adm 7 77.5 46 18 210 
    24hrs 7.1 260 48 20.8 180 
    48hrs 6.9 130 39 21 150 
                
44 Tholathai Adm 7.3 81.5 48 18 240 
    24hrs 7.2 260 45 24 220 
    48hrs 6.2 210 41 32 100 
                
45 Murali Adm 7.1 75.5 47 19 160 
    24hrs 7 330 38 26 150 
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    48hrs           
                
46 Uma sekar Adm 7.3 95 45 24 396 
    24hrs 7 100 50 18 150 
    48hrs 6.9 120 55 18 100 
                
47 Ambika Adm 7.1 72 48 24 250 
    24hrs 6.9 330 40 16 160 
    48hrs           
                
48 Pavala Rani Adm 7.34 96.5 44 26 396 
    24hrs 7.32 97 38 22 410 
    48hrs 7.3 92 41.5 23 420 
                
49 Rajeshwari Adm 6.9 68.5 45 18 160 
    24hrs 7.1 62 40 12 120 
    48hrs           
                
50 Janaki Adm 7.3 95 40 24 410 
    24hrs 7.34 96.5 38 22 390 
    48hrs 7.1 95.5 36 21 400 
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1 Sujatha Adm 7000 4550 2330 150000 10 2.0 18 0.8 0.6 3 88 15 1
24Hrs 4500 3250 3110 201040 9.8 1.0 22 1.1 0.6 4 70 14 NARDS 1
48Hrs 8800 3500 2210 160000 9 1.6 26 1.2 0.8 5 75 14 1
2 Iyyappan Adm 5600 3450 2410 170000 9.2 1.4 23 1.2 0.9 3 90 15 1
24Hrs 5600 4210 2102 140500 9.5 2.0 40 1.3 0.8 2 95 14 NARDS 1
48Hrs 6040 3521 3000 160000 8.5 1.2 32 1 1.2 4 96 15 1
3 Dilli Babu Adm 8000 8000 1000 90000 9.1 8.0 65 1.5 1.4 6 70 8 2
24Hrs 12000 9000 1200 80000 9 7.5 95 2 1.9 10 65 3 ARDS 2
48Hrs 17000 8500 1200 75000 8.8 7.1 105 4.5 2.1 12 65 3 2
4 LoganathanAdm 9000 8200 1100 95000 8.8 7.5 60 1.6 1.5 7 65 7
24Hrs 18000 9500 1250 84000 9.1 7.6 91 2.1 2 11 62 3 24HRS
48Hrs
5 Menaka Adm 7000 3330 1600 140000 8.7 2.1 33 1.2 0.6 3 98 15 1
24Hrs 3650 3500 2350 163500 9.2 1.5 24 0.8 0.8 4 90 14 NARDS 1
48Hrs 5600 4120 2600 160000 9.6 1.6 23 1.4 1 6 90 14 1
6 Kumar Adm 7000 3500 1800 150000 8.9 1.9 45 1 1.2 4 90 5 1
24Hrs 6500 2800 1200 170000 8.3 2.3 42 0.9 1.4 5 95 14 NARDS 1
48Hrs 6500 3100 1500 130000 8.5 2.1 40 0.9 1.2 5 80 14 1
7 MasilamaniAdm 15000 5200 1200 95000 10 4.3 95 5.2 6.5 5.5 55 8 2
24Hrs 18000 5000 900 55000 9.8 5.6 120 6.5 7 6.5 65 3 ARDS 2
48Hrs 2
8 Mohana Adm 22000 5200 1300 65000 12 4.0 140 7 6.5 10 55 3 ADMISSION
24Hrs
48Hrs
9 Baskaran Adm 18000 5200 1200 95000 9 4.3 140 7.5 6.5 8 55 8 2
24Hrs 20000 5000 950 65000 10 5.3 150 6.7 6.5 10 65 3 ARDS 2
48Hrs 2
10 Arul Adm 6000 3500 1500 150000 9.2 2.3 35 0.6 0.9 4 98 15 1
24Hrs 5020 3200 1500 170000 9 2.1 25 0.4 0.7 3 96 14 NARDS 1
48Hrs 3600 4000 2200 180000 8.9 1.8 40 0.7 0.6 4 95 15 1
11 Rani Adm 18000 5200 950 55000 9.3 5.5 120 6.5 6.5 10 65 3 ADMISSION
24Hrs
48Hrs
12 Ethiraj Adm 20000 5200 1000 68000 11.2 5.2 140 7 6.5 10 65 13 ADMISSION
24Hrs
48Hrs
13 Kannan Adm 18000 5200 900 75000 10 5.8 100 6 6.2 10 65 3 24HRS
24Hrs 20000 5200 900 65000 11 5.8 120 5.9 5.5 10 55 3
48Hrs
14 jagan Adm 20000 5600 900 55000 11 6.2 150 8.3 7.1 10 50 3 ADMISSION
24Hrs
48Hrs
15 Sharmila Adm 15000 5300 900 95000 9 5.9 100 4.9 6.5 12 75 8 2
24Hrs 18000 6500 920 100000 9.1 7.1 120 5.1 7 12 85 4 ARDS 2
48Hrs 15000 5000 800 75000 9.1 6.3 110 5.4 7.2 10 85 4 2
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16 ManjupriyaAdm 15000 5200 950 85000 9.1 5.5 100 5.2 6.5 8 90 8 2
24Hrs 18000 6200 900 85000 9 6.9 120 6.5 6.3 12 55 3 ARDS 2
48Hrs 19000 5200 900 90000 9 5.8 110 8.5 9 12 60 3 2
17 Asok Adm 13000 5200 900 75000 9 5.8 95 4.5 7.6 8 95 8 2
24Hrs 15000 4800 980 50000 9 4.9 120 8 0.5 10 55 3 ARDS 2
48Hrs 15000 5200 930 55000 9 5.6 120 8.2 6.5 12 50 3 2
18 Reena Adm 18000 5200 900 75000 9 5.8 98 6.5 4.5 8 65 3
24Hrs 20000 5000 950 50000 9.1 5.3 120 7 6.5 10 55 3 24HRS
48Hrs
19 prasanna Adm 18000 5200 1000 68000 8.9 5.2 20 4.5 6.5 10 75 8 2
24Hrs 200000 5000 1200 65000 9.2 4.2 100 6.5 7 8 70 3 ARDS 2
48Hrs 20000 5200 960 65000 9.2 5.4 120 6.8 7.1 10 65 3 2
20 Thiagu Adm 19000 5200 1000 98000 8.9 5.2 120 4.5 6.5 8 95 3
24hrs 22000 5500 920 55000 8.1 6.0 150 6.5 7.5 10 60 3 24HRS
48hrs
21 kamalanathanAdm 3500 5000 2500 150000 8.9 2.0 33 0.8 0.6 4 95 15 1
24hrs 4520 4500 2000 200000 9 2.3 35 0.7 0.8 4 90 14 NARDS 1
48hrs 5500 4250 2750 180000 9.1 1.5 25 0.6 0.9 5 85 14 1
22 Yuvaraj Adm 18000 6000 1000 95000 8.9 6.0 140 6.5 6.3 6 65 10 2
24hrs 20000 5200 920 50000 9 5.7 120 8 6.6 10 50 3 ARDS 2
48hrs 18000 5200 900 55000 8.9 5.8 100 8.2 7.4 12 55 3 2
23 Sowmiya Adm 4500 3500 2000 180000 9.1 1.8 35 1 0.9 4 96 15 1
24hrs 15000 5600 2500 160000 9.2 2.2 40 0.9 0 4 95 15 NARDS 1
48hrs 18000 5200 2200 170000 9 2.4 35 1 1 4 90 15 1
24 Subramani Adm 5600 3500 2200 160000 9 1.6 35 1.2 0.9 4 90 10 2
24hrs 6200 2500 2000 170000 9.1 1.3 120 7 6.5 12 65 8 ARDS 2
48hrs 4500 4100 2100 160000 9.2 2.0 160 6.5 6 10 60 8 2
25 Mohan Adm 19000 4500 1000 95000 9 4.5 140 5.5 6.5 4 60 8
24hrs 20000 5000 950 50000 8.9 5.3 120 6.8 7.5 10 60 3 24HRS
48hrs
26 Guruvayi Adm 17000 4200 1000 95000 9 4.2 95 4.6 6.6 8 65 4 2
24hrs 19000 5550 1200 50000 9.2 4.6 110 7 7 10 50 3 ARDS 2
48hrs 19000 5000 1000 55000 9.2 5.0 120 8 8 10 55 3 2
27 Tirumalai Adm 18000 5100 1020 100000 9 5.0 120 4.5 6.5 8 65 8
24hrs 22000 5400 1200 75000 9.1 4.5 140 7.5 8 10 55 3 24HRS
48hrs
28 Devi Adm 5000 4500 2200 180000 8.9 2.0 45 1.2 1.2 4 95 15 1
24hrs 4500 4300 2100 150000 9 2.0 35 0.9 1 8 90 15 NARDS 1
48hrs 3500 4200 2300 150000 9 1.8 25 1.2 1 4 95 15 1
29 Vijaya kumarAdm 7000 4500 1500 120000 9.1 3.0 45 1.9 2.1 5 65 12 ADMISSION
24hrs
48hrs
30 Reshma Adm 18000 4300 900 95000 8.9 4.8 140 4.5 5.6 8 65 8 2
24hrs 19000 4200 900 45000 9.2 4.7 150 5.6 7 10 55 3 ARDS 2
48hrs 20000 5200 990 55000 9.2 5.3 140 5.5 6.5 0 65 3 2
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31 Poornima Adm 6500 4200 2000 160000 9.1 2.1 45 1.2 1 3 95 15 1
24hrs 5600 4200 2220 180000 9 1.9 38 0.9 1.2 4 95 14 NARDS 1
48hrs 5500 3800 2500 170000 0.9 1.5 45 0.9 1 4 94 15 1
32 Pandian Adm 15000 4800 1200 90000 8.9 4.0 120 3.3 3.5 6 55 10 2
24hrs 14000 4600 1000 85000 9 4.6 110 3.5 4.5 8 60 8 ARDS 2
48hrs 18000 4900 900 80000 9.1 5.4 140 6.8 6.8 10 65 3 2
33 VenkatesanAdm 15000 4500 1000 95000 9 4.5 100 3.3 3.6 6 85 8 2
24hrs 14000 5210 900 98000 8.9 5.8 120 7.5 6.5 9 50 3 ARDS 2
48hrs 14500 5200 920 45000 8.8 5.7 140 7.8 6.8 9 55 3 2
34 Yuvaraj Adm 18000 5200 1100 75000 9 4.7 110 4.5 5.5 6 60 8
24hrs 18500 4800 900 45000 8.9 5.3 140 4.6 6.5 6 50 3 24HRS
48hrs
35 Sumathi Adm 18000 5400 1200 85000 9 4.5 95 3.3 4.5 5 60 8
24hrs 22000 4800 900 45000 9.1 5.3 110 5.6 5.6 8 55 3 24HRS
48hrs
36 Saranya Adm 7800 4300 1200 95000 8 3.6 85 2.1 3.3 4 65 8 2
24hrs 5400 5200 1000 85000 8.5 5.2 120 5.5 4.5 6 55 3 ARDS 2
48hrs 13000 5800 920 45000 9 6.3 140 6.5 6.5 8 50 3 2
37 Velu Adm 5600 4200 2200 180000 9.1 1.9 35 0.9 0.9 3 95 15 1
24hrs 6300 4500 2100 170000 8.9 2.1 45 1 1 3 90 15 NARDS 1
48hrs 5200 3800 2000 150000 8.6 1.9 45 0.8 0.6 4 88 15 1
38 Vanmathi Adm 14000 4500 1000 80000 8.9 4.5 120 2.8 3.5 9 50 3 2
24hrs 18000 4200 1200 75000 9 3.5 110 3.5 6.1 10 55 3 ARDS 2
48hrs 19000 5200 990 55000 9.5 5.3 120 6.5 5.5 12 55 3 2
39 Naveen kumarAdm 5800 4300 2300 175000 9 1.9 35 0.8 1.2 4 90 15 1
24hrs 6600 4700 2200 168000 8.8 2.1 33 0.7 0.9 3 88 14 NARDS 1
48hrs 5400 4000 2300 149000 8.7 1.7 40 1.2 0.8 4 90 14 1
40 Dillibabu Adm 11000 5200 1000 85000 8.5 5.2 85 2.5 3.2 4 65 8
24hrs 18000 6200 820 65000 8.2 7.6 120 5.8 4.5 4 50 3 24HRS
48hrs 8
41 Anjali Adm 5600 5200 1000 98000 8.9 5.2 85 2.5 2.2 4 65 8
24hrs 20000 5200 920 75000 8.5 5.7 120 5.5 7 6 55 3 24 HRS
48hrs
42 Leela Adm 5700 4200 2200 160000 9 1.9 40 1.2 0.8 4 88 15 2
24hrs 15000 5500 1200 98000 8.2 4.6 150 5.5 6.5 12 65 8 ARDS 2
48hrs 18000 4500 1000 55000 8.8 4.5 120 6.5 5.5 10 65 8 2
43 BalamuruganAdm 8500 4500 1000 100000 9 4.5 55 1.6 1.2 4 85 13 2
24hrs 7200 5200 900 85000 8.9 5.8 98 2.6 2.5 8 50 8 ARDS 2
48hrs 11000 5500 800 80000 8.8 6.9 210 4.6 2.8 8 55 3 2
44 Tholathai Adm 6200 4500 1300 90000 9 3.5 65 1.8 1.8 5 85 15 2
24hrs 8500 3800 1400 95000 9.1 2.7 55 2.2 2.5 6 80 10 ARDS 2
48hrs 16000 3900 1200 85000 3.3 60 2.3 3 8 60 3 2
45 Murali Adm 15000 4200 1200 97000 8.3 3.5 105 3.3 2.3 4 50 7
24hrs 17000 5200 1300 55000 8.2 4.0 120 7.5 7.2 8 55 3 24HRS 2
48hrs
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46 Uma sekar Adm 5200 4600 2000 175000 8.9 2.3 43 1.1 1 5 90 15 2
24hrs 4600 4200 1950 165000 9 2.2 100 5.5 5 10 65 8 ARDS 2
48hrs 15000 5600 1000 148000 9 5.6 120 6 5.3 10 50 3 2
47 Ambika Adm 12000 4500 1000 98000 8.9 4.5 120 2.3 2.2 6 50 8
24hrs 15000 4300 1100 45000 8.8 3.9 105 3.3 4.5 8 55 3 24HRS
48hrs
48 Pavala RaniAdm 6600 4300 2100 165000 9.1 2.0 36 1 0.9 4 90 15 1
24hrs 5700 4700 2200 175000 9 2.1 44 0.9 1 3 87 14 NARDS 1
48hrs 5600 3900 2100 168000 0.9 1.9 41 1.1 0.7 4 88 15 1
49 Rajeshwari Adm 10500 3500 1200 100000 9 2.9 140 3 2.5 6 60 7 24HRS
24hrs 22000 3800 1000 105000 8.1 3.8 95 5.5 6.5 8 55 3
48hrs
50 Janaki Adm 5900 4100 2150 170000 9.1 1.9 36 0.9 1 4 93 15 1
24hrs 6400 4600 2050 165000 8.9 2.2 44 1.1 1 5 88 15 NARDS 1
48hrs 5700 3900 2300 175000 8.8 1.7 41 1 0.9 3 89 14 1
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Adm 11842.0 4758.6 1390.2 ###### 9.2 4.0 81.6 3.2 3.5 6.0 74.8 9.6
24Hrs 17473.1 4907.1 1385.8 ###### 9.0 4.2 93.5 4.2 4.3 7.6 67.8 7.0
48Hrs 11154.4 4390.3 1483.4 ###### 7.6 3.6 81.0 3.8 3.6 7.1 67.8 7.8
S.NO DURATION TIME
LEUCO
CYTES/
cumm
NEUTR
OPHIL/
cumm
LYMPH
OCYTE/
cumm
PLATEL
ET/cu
mm HB(mg/dl)
NLR 
Ratio 
(Neutro
phil/LyUREA (mg/dl)
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24Hrs 6145.4 4158.5 2125.5 ##### 9.0 2.0 35.9 0.9 0.9 4.0 89.9 14.3
48Hrs 6533.8 3945.5 2304.6 ##### 7.7 1.7 35.2 1.0 0.9 4.3 88.8 14.5
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32 MEMBERS24Hrs ###### 5211.3 1085.3 ##### 9.0 5.1 116.8 5.6 5.6 9.0 58.8 4.0
19 MEMBERS48Hrs ###### 4694.7 921.6 ##### 7.6 4.8 112.4 5.7 5.4 9.0 53.4 3.3
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FOR ALL 24Hrs
13 MEMBERS24Hrs
32 MEMBERS24Hrs
13 MEMBERS
FOR ALL PATIENTS
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